oxybutynin has been researched along with Bladder, Overactive in 184 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effect of oxybutynin patch versus β3-adrenoceptor agonist mirabegron on nocturia-related quality of life in female overactive bladder patients." | 9.41 | Effect of oxybutynin patch versus mirabegron on nocturia-related quality of life in female overactive bladder patients: A multicenter randomized trial. ( Furuhata, M; Hosaka, K; Ishizuka, O; Minagawa, T; Nakagawa, T; Ogawa, T; Saito, T; Suzuki, T, 2021) |
| "To investigate the efficacy of a once-daily oxybutynin patch for nocturia, and its influence on sleep quality in patients with overactive bladder." | 9.20 | Once-daily oxybutynin patch improves nocturia and sleep quality in Japanese patients with overactive bladder: Post-hoc analysis of a phase III randomized clinical trial. ( Higo, N; Ishizuka, O; Masegi, Y; Minami, H; Seki, N; Takahashi, S; Yamaguchi, A; Yamaguchi, O; Yamanishi, T; Yokoyama, O; Yoshida, M, 2015) |
| " In this post hoc analysis we evaluated the efficacy and tolerability of trospium chloride treatment for urinary urge incontinence (UUI) with focus on flexible dosing." | 9.14 | Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. ( Bödeker, RH; Madersbacher, H; Neumeister, C; Zellner, M, 2010) |
| "Cizolirtine citrate is a promising agent in the treatment of OAB with urinary incontinence." | 9.14 | Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. ( Abadías, M; Brod'ák, M; Pavlík, I; Schraml, P; Sust, M; Villoria, J; Vsetica, J; Zát'ura, F, 2010) |
| "To compare, in a retrospective observational cohort study, the efficacy, tolerability and safety of propiverine and oxybutynin in children with urge incontinence (UI) due to overactive bladder." | 7.76 | Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study. ( Alloussi, S; Bock, P; Braun, R; Gerhardt, U; Heinrich, M; Hellmis, E; Horn, W; Madersbacher, H; Marschall-Kehrel, D; Mürtz, G; Niklas, K; Raabe, M; Rössler, T; Schultz-Lampel, D; Seibt, B; Siemer, S; Strugala, G; Walter, H; Wiedeking, B, 2010) |
| " In this study, we investigated the effect of the recently developed P2X3 and P2X2/3 receptor antagonist A-317491 on cyclophosphamide (CYP)-induced cystitis to determine whether a P2X receptor antagonist could be beneficial for the treatment of bladder overactivity induced by CYP." | 7.74 | Therapeutic effects of the putative P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats. ( Ikeda, M; Ito, K; Iwami, A; Katsura, H, 2008) |
| "Intravesical instillation of TRG-100 was found to be safe and efficient in reducing pain and irritative bladder symptoms in our study population." | 5.91 | Open Label, Pilot Evaluation of the Safety and Efficacy of Intravesical Sustained Release System of Lidocaine and Oxybutynin (TRG-100) for Patients With Interstitial Cystitis/Bladder Pain Syndrome, Overactive Bladder and Patients With Retained Ureteral St ( Ala-Adin, N; Chertin, B; Dothan, D; Gordon, A; Hatumi, S; Kafka, I; Malchi, N; Moldwin, R; Nassar, T; Perez, D; Raisin, G; Shenfeld, O; Touitou, D, 2023) |
| "To investigate the effect of oxybutynin patch versus β3-adrenoceptor agonist mirabegron on nocturia-related quality of life in female overactive bladder patients." | 5.41 | Effect of oxybutynin patch versus mirabegron on nocturia-related quality of life in female overactive bladder patients: A multicenter randomized trial. ( Furuhata, M; Hosaka, K; Ishizuka, O; Minagawa, T; Nakagawa, T; Ogawa, T; Saito, T; Suzuki, T, 2021) |
| "The QT changes increased cardiac arrhythmia in children." | 5.39 | Does oxybutynin hydrochloride cause arrhythmia in children with bladder dysfunction? ( Arslan, D; Ciftci, I; Cimen, D; Gunduz, M; Oran, B; Peru, H, 2013) |
| "The purpose of this study was to evaluate the efficiency of the anticholinergic therapy with oxybutynin and the effects of daily transcutaneous tibial nerve stimulation (TTNS) on the quality of life of patients with an overactive bladder (OAB) and multiple sclerosis (MS)." | 5.30 | Effects of Treating an Overactive Urinary Bladder in Patients with Multiple Sclerosis. ( Čičkušić, A; Delalić, A; Hodžić, R; Imamović, M; Imamović, S; Zonić-Imamović, M, 2019) |
| "To investigate the efficacy of a once-daily oxybutynin patch for nocturia, and its influence on sleep quality in patients with overactive bladder." | 5.20 | Once-daily oxybutynin patch improves nocturia and sleep quality in Japanese patients with overactive bladder: Post-hoc analysis of a phase III randomized clinical trial. ( Higo, N; Ishizuka, O; Masegi, Y; Minami, H; Seki, N; Takahashi, S; Yamaguchi, A; Yamaguchi, O; Yamanishi, T; Yokoyama, O; Yoshida, M, 2015) |
| "Seventy girls and 27 boys with clinically diagnosed OAB and urge incontinence were randomly allocated to placebo, oxybutynin, or bladder training (branch I), and 89 girls and 16 boys with clinically diagnosed DV to either cognitive treatment or pelvic floor training (branch II)." | 5.19 | Multi-center randomized controlled trial of cognitive treatment, placebo, oxybutynin, bladder training, and pelvic floor training in children with functional urinary incontinence. ( Bachmann, H; Bael, A; de Jong, TP; Hirche, H; Hjälmås, K; Hoebeke, P; Jodal, U; John, U; Lax, H; Misselwitz, J; Nijman, RJ; Tamminen-Möbius, T; van Gool, JD; Walle, JV; Winkler-Seinstra, P, 2014) |
| " In this post hoc analysis we evaluated the efficacy and tolerability of trospium chloride treatment for urinary urge incontinence (UUI) with focus on flexible dosing." | 5.14 | Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. ( Bödeker, RH; Madersbacher, H; Neumeister, C; Zellner, M, 2010) |
| "Cizolirtine citrate is a promising agent in the treatment of OAB with urinary incontinence." | 5.14 | Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. ( Abadías, M; Brod'ák, M; Pavlík, I; Schraml, P; Sust, M; Villoria, J; Vsetica, J; Zát'ura, F, 2010) |
| "Older adults receiving solifenacin and darifenacin in the 6 mo prior to diagnosis, and those receiving solifenacin, darifenacin, tolterodine, or fesoterodine in the year prior to diagnosis, have increased odds of incident dementia, compared with those receiving mirabegron." | 4.12 | Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study. ( Gomes, T; Herschorn, S; Jarvi, K; Juurlink, D; Matta, R; Nam, RK, 2022) |
| "To compare, in a retrospective observational cohort study, the efficacy, tolerability and safety of propiverine and oxybutynin in children with urge incontinence (UI) due to overactive bladder." | 3.76 | Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study. ( Alloussi, S; Bock, P; Braun, R; Gerhardt, U; Heinrich, M; Hellmis, E; Horn, W; Madersbacher, H; Marschall-Kehrel, D; Mürtz, G; Niklas, K; Raabe, M; Rössler, T; Schultz-Lampel, D; Seibt, B; Siemer, S; Strugala, G; Walter, H; Wiedeking, B, 2010) |
| " In this study, we investigated the effect of the recently developed P2X3 and P2X2/3 receptor antagonist A-317491 on cyclophosphamide (CYP)-induced cystitis to determine whether a P2X receptor antagonist could be beneficial for the treatment of bladder overactivity induced by CYP." | 3.74 | Therapeutic effects of the putative P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats. ( Ikeda, M; Ito, K; Iwami, A; Katsura, H, 2008) |
| "A retrospective analysis of patients with OAB who initiated treatment with tolterodine extended release (ER), oxybutynin ER, or oxybutynin immediate release (IR) between January 2001 and December 2002 was conducted to evaluate the frequency, relative risk, resource utilization, and costs related to three specific comorbidities associated with OAB: urinary tract infections (UTIs), depression, and fracture." | 3.73 | Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin. ( Girase, P; Jumadilova, Z; Ollendorf, DA; Varadharajan, S, 2006) |
| "Fesoterodine has a favorable benefit-risk profile in 6‒<18-year-old patients with NDO and may represent an additional option for pediatric NDO treatment." | 3.30 | Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study. ( Crook, TJ; Darekar, A; Jones, P; Kitta, T; Lindsay, M; Malhotra, B; Mallen, S; Nieto, A; Shahin, MH, 2023) |
| "Anticholinergic overactive bladder (OAB) medications have been studied in large observational studies to determine if they are associated with a greater risk of mortality (potentially because of their effects on the heart or the brain)." | 3.01 | The Differential Risk of Mortality Among Users of Overactive Bladder Anticholinergic Medications and β3 Agonists. ( Welk, B, 2023) |
| "The first-line drug treatment for lower urinary tract symptoms, orally administered antimuscarinics, fails to reach the equilibrium dissociation constant of muscarinic receptors even at their maximum plasma concentration and tends to evoke a half-maximal response at a muscarinic receptor occupancy of just 0." | 3.01 | Treating Lower Urinary Tract Symptoms in Older Adults: Intravesical Options. ( Beckel, J; Chancellor, M; Chermansky, C; Cho, KJ; Ganguly, A; Hashimoto, M; Kanai, A; Kaufman, J; Tyagi, P; Tyagi, S; Yoshimura, N, 2023) |
| " Adverse drug reactions (ADR) were collected and an evaluation of anticholinergic effects was conducted." | 2.82 | Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: A randomized, prospective, controlled multi-center trial. ( Albrecht, U; Reitz, A; Schnitker, J; Schröder, A; Stein, R, 2016) |
| "Oxybutynin was more effective for decreasing voiding frequency." | 2.80 | Transcutaneous parasacral electrical stimulation vs oxybutynin for the treatment of overactive bladder in children: a randomized clinical trial. ( Barroso Júnior, U; Bastos Netto, JM; Cunha, C; de Oliveira, LF; Lordelo, P; Moraes, M; Quintiliano, F; Veiga, ML, 2015) |
| "To evaluate Overactive bladder (OAB) with detrusor overactivity (DOA) following oxybutynin or tolterodine treatment in recommended doses at a four-week course." | 2.80 | Prominent complaint: a guide to medical therapy of overactive bladder syndrome in older women. ( Azimi Nekoo, E; Ghanbari, Z; Haghollahi, F; Hashemi, S; Jafarabadi, M; Nemati, M, 2015) |
| " Safety was measured in terms of treatment emergent adverse events, laboratory, physical, gynecologic examinations, electrocardiogram and vital signs." | 2.79 | A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women. ( Gittelman, M; Seidman, L; Weiss, H, 2014) |
| "To evaluate cognitive effects during chronic stable dosing with solifenacin and oxybutynin versus placebo in older (≥75 yr) subjects with MCI." | 2.78 | Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. ( Compion, G; Dale, M; Stow, B; Tretter, R; Wagg, A, 2013) |
| " Dry mouth was the only drug-related adverse event significantly more common with OTG (7." | 2.77 | Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome. ( Caramelli, KE; Davila, GW; Hoel, G; Lucente, VR; Sand, PK; Thomas, H, 2012) |
| "Oxybutynin is a common antimuscarinic therapy for overactive bladder." | 2.77 | Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study. ( Dahl, NV; Kay, GG; MacDiarmid, S; McIlwain, M; Staskin, DR, 2012) |
| " Clinical visits were required for pharmacokinetic sampling, supervision of OTG self-application on pharmacokinetic sampling days, showering, sunscreen application and transference experiments." | 2.76 | Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference. ( Caramelli, KE; Dmochowski, RR; Hoel, G; Newman, DK; Rudy, DC; Sand, PK; Thomas, H, 2011) |
| " The incidence of adverse events in the tolterodine-treated group (28%) was significantly lower than that in the oxybutnin-treated group (57%) (P<0." | 2.76 | [Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder]. ( Chen, CJ; Deng, YJ; Ge, Z; Guo, YF; Lu, RG; Ma, G; Wang, LX; Zhu, HB, 2011) |
| "The Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial was a two-site randomized, controlled, equivalence trial with 4-week alpha-blocker run-in." | 2.76 | Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial. ( Burgio, KL; Colli, J; Goode, PS; Hammontree, L; Johnson, TM; Markland, AD; Ouslander, JG; Redden, DT; Vaughan, CP, 2011) |
| "Postmenopausal women with an overactive bladder were recruited from the general gynecology clinic." | 2.76 | Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. ( Felix, JC; Leegant, AR; Mishell, DR; Nelken, RS; Ozel, BZ, 2011) |
| " Safety was monitored through adverse event reporting." | 2.74 | Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. ( Caramelli, KE; Dmochowski, RR; Hoel, G; Macdiarmid, SA; Sand, PK; Staskin, DR; Thomas, H, 2009) |
| "Children with refractory overactive bladder and incontinence were included in a prospective, open label protocol." | 2.74 | Double anticholinergic therapy for refractory overactive bladder. ( Bolduc, S; Hamel, M; Lamontagne, P; Lebel, S; Moore, K, 2009) |
| " There were 12 treatment related adverse events noted with transdermal oxybutynin (mild skin reaction) and 1 with oral oxybutynin (vasodilatation)." | 2.74 | Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. ( Cartwright, PC; Coplen, DE; Finan, E; Hoel, G; Kogan, BA; Volinn, W, 2009) |
| "To evaluate the efficacy and tolerability of extended-release oxybutynin in combination with the alpha1-blocker tamsulosin in reducing lower urinary tract symptoms in men." | 2.73 | Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. ( Aquilina, JW; Armstrong, RB; Chen, A; MacDiarmid, SA; Nitti, VW; Orman, C; Peters, KM, 2008) |
| "or oxybutynin 5mg t." | 2.73 | Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study. ( Arnold, EP; Kramer, G; Mürtz, G; Schnabel, F; Stöhrer, M; Wyndaele, JJ, 2007) |
| "2%) reported no treatment-related adverse events; two men (0." | 2.73 | Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. ( Dahl, NV; Polishuk, PV; Rosenberg, MT; Staskin, DR; Zinner, NR, 2008) |
| "Complete freedom from urge incontinence was reported by significantly more patients taking oxybutynin than tolterodine at last observation (23." | 2.72 | Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. ( Anderson, RU; Barada, JH; Goldberg, RP; Kell, S; MacDiarmid, S; Serels, S, 2006) |
| "Oxybutynin was more effective than placebo." | 2.72 | Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial. ( Chen, MC; Chih, SY; Wang, AC, 2006) |
| "Oxybutynin was shown to have largest effect towards the decline of MMSE score [Mean difference: -2." | 2.66 | Effect of Antimuscarinic Drugs on Cognitive Functions in the Management of Overactive Bladder in Elderly. ( Rahardjo, HE; Rangganata, E; Widia, F, 2020) |
| "Overactive bladder affects a significant portion of the population and results in prescribing of numerous medications for its treatment." | 2.53 | Delivery methods for drugs used in the treatment of overactive bladder. ( Dmochowski, RR; Padmanabhan, P; Scott, K, 2016) |
| "Darifenacin has a strong affinity for the M3 receptor in the bladder, while having a weak affinity for the M1 receptor commonly found in the brain." | 2.52 | Treatment of Overactive Bladder in the Elderly Female: The Case for Trospium, Oxybutynin, Fesoterodine and Darifenacin. ( Gomelsky, A; McFerren, SC, 2015) |
| "Around 16% to 45% of adults have overactive bladder symptoms (urgency with frequency and/or urge incontinence - 'overactive bladder syndrome')." | 2.48 | Which anticholinergic drug for overactive bladder symptoms in adults. ( Cody, JD; Ellis, G; Hay-Smith, EJ; Herbison, GP; Madhuvrata, P, 2012) |
| "Propiverine was at least as effective as oxybutynin but with a better tolerability profile even in the pediatric setting." | 2.48 | An overview on mixed action drugs for the treatment of overactive bladder and detrusor overactivity. ( Artibani, W; Asimakopoulos, AD; Carone, R; Cerruto, MA; Del Popolo, G; Finazzi-Agrò, E; La Martina, M, 2012) |
| " The AMs used to treat OAB differ in their pharmacological profiles, which may affect their potential for causing adverse effects (AEs)." | 2.48 | Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. ( Alessandri, F; Candiani, M; Ferrero, S; Leone Roberti Maggiore, U; Origoni, M; Remorgida, V; Salvatore, S; Venturini, PL, 2012) |
| "Overactive bladder is a common condition that has a negative impact on the quality of life of the affected individuals." | 2.45 | Comparison between oxybutynin, functional electrical stimulation and pelvic floor training for treatment of detrusor overactivity in women: a review. ( Arruda, RM; Castro, R; Girão, MJ; Sartori, M, 2009) |
| " This article summarizes the efficacy, contraindications, precautions, dosing and common side effects of these agents." | 2.44 | Pharmacologic management of overactive bladder. ( Hilas, O; Lam, S, 2007) |
| "This is usually due to overactive bladder syndrome (defined as urgency, with or without urge incontinence, and usually with frequency and nocturia), which occurs in around 12% of adults, and is similarly prevalent in men and women." | 2.44 | Update on drugs for overactive bladder syndrome. ( , 2007) |
| "Overactive bladder is a common and disabling problem." | 2.44 | Transdermal oxybutynin: a review. ( Patel, HR; Shaw, GL, 2007) |
| " Because older individuals typically take multiple medications, clinicians must pay special attention to potential drug-drug interactions that may cause adverse events or alter drug efficacy." | 2.44 | Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential. ( Chancellor, MB; de Miguel, F, 2007) |
| "Millions of men suffer from overactive bladder and lower urinary tract symptoms." | 2.44 | Male overactive bladder: the role of urodynamics and anticholinergics. ( MacDiarmid, S; Rogers, A, 2007) |
| "Oxybutynin has been used for the management of detrusor overactivity for over 30 years and has withstood medical scrutiny and the test of time throughout the world." | 2.43 | Oxybutynin in detrusor overactivity. ( Diokno, A; Ingber, M, 2006) |
| "Overactive bladder is a dreadful syndrome that affects a considerable number of patients." | 2.43 | Transdermal oxybutynin in the treatment of overactive bladder. ( Davila, GW, 2006) |
| "Intravesical instillation of TRG-100 was found to be safe and efficient in reducing pain and irritative bladder symptoms in our study population." | 1.91 | Open Label, Pilot Evaluation of the Safety and Efficacy of Intravesical Sustained Release System of Lidocaine and Oxybutynin (TRG-100) for Patients With Interstitial Cystitis/Bladder Pain Syndrome, Overactive Bladder and Patients With Retained Ureteral St ( Ala-Adin, N; Chertin, B; Dothan, D; Gordon, A; Hatumi, S; Kafka, I; Malchi, N; Moldwin, R; Nassar, T; Perez, D; Raisin, G; Shenfeld, O; Touitou, D, 2023) |
| "To assess the prescribing practices for overactive bladder (OAB) pharmacotherapy based on the prescription trend analysis across different specialties of India." | 1.91 | [Assessment of prescribing practices in overactive bladder pharmacotherapy across different specialties of India: a prescription trend analysis]. ( Hiren Prajapati, HP; Krunal Vishavadia, KV; Madhu Sharma, MS; Sandip Solanki, SS, 2023) |
| " Transdermal administration is a more ideal route replacing oral administration to resolve problems of low bioavailability and severe side effects." | 1.72 | Oxybutynin nanosuspension gel for enhanced transdermal treatment for overactive bladder syndrome. ( Hu, C; Ling, J; Lv, H; Sheng, Y; Zhang, S; Zhang, Z, 2022) |
| "Older patients with overactive bladder under antimuscarinic treatment are especially susceptible to cognitive impairment." | 1.51 | Cognitive function assessment in elderly patients with overactive bladder treated with transdermal oxybutynin. ( Arlandis-Guzman, S; Batista-Miranda, JE; Casas Nebra, J; El Khoury Moreno, R; Errando-Smet, C; Gonzalez Garcia, O; Leva Vallejo, M; Morales Solchaga, G; Müller-Arteaga, C; Zubiaur Libano, C, 2019) |
| "All medical records, including the Overactive Bladder Symptom score (OABSS), the modified Indevus Urgency Severity Scale and the International Prostate Symptoms score (IPSS) questionnaires, and uroflowmetry parameters were reviewed at each visit." | 1.48 | Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year. ( Hsiao, SM; Kuo, HC; Lin, HH, 2018) |
| " This study reported the results of treatment with a high dosage of a single drug in children with refractory detrusor overactivity (DO)." | 1.43 | Combined low-dose antimuscarinics for refractory detrusor overactivity in children. ( Fahmy, A; Mahfouz, W; Mokhless, I; Rhashad, H; Youssif, M, 2016) |
| " However, as yet no data are available on long-term use and outcome." | 1.42 | Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters. ( Buyse, G; Christiaens, MH; Hirche, H; Humblet, M; Jansen, K; van Gool, JD; Verpoorten, C, 2015) |
| "Incidences of overactive bladder (OAB) and cognitive dysfunction increase with aging." | 1.42 | Influence of antimuscarinic therapy on cognitive functions and quality of life in geriatric patients treated for overactive bladder. ( Ariogul, S; Cankurtaran, E; Cankurtaran, M; Ergen, A; Esin, E; Halil, M; Kuyumcu, ME; Ozcan, M; Ulger, Z; Yavuz, BB; Yeşil, Y, 2015) |
| "The mean overactive bladder symptom score of these patients was 6." | 1.40 | Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study. ( Akino, H; Fujiuchi, Y; Fuse, H; Kitagawa, Y; Miyazawa, K; Namiki, M; Suzuki, K; Yokoyama, O, 2014) |
| ", whereas 47 (45,2%) used a lower dosage and 28 (26." | 1.39 | The use of oxybutynin in patients treated by means of botulinum neurotoxin A for neurogenic detrusor overactivity: an observational study. ( De Nunzio, C; Del Popolo, G; Finazzi-Agrò, E; Finita Celso, M; Lombardi, G; Perugia, C; Topazio, L, 2013) |
| "The QT changes increased cardiac arrhythmia in children." | 1.39 | Does oxybutynin hydrochloride cause arrhythmia in children with bladder dysfunction? ( Arslan, D; Ciftci, I; Cimen, D; Gunduz, M; Oran, B; Peru, H, 2013) |
| "Oxybutynin (OXY) is an antimuscarinic agent that has been available for more than 30 years in the treatment of OAB patients." | 1.39 | Development of long-acting bioadhesive vaginal gels of oxybutynin: formulation, in vitro and in vivo evaluations. ( Acartürk, F; Erdoğan, D; Tuğcu-Demiröz, F, 2013) |
| "In this multicentre, prospective, observational, flexible-dosing study, the dosage of oxybutynin ER for each patient was adjusted after discussions of efficacy and tolerability between doctor and patient, over a 12 week treatment period." | 1.38 | Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: a multicentre, open-label, prospective observational study. ( Choo, MS; Han, JY; Lee, KS; Yoo, DS, 2012) |
| "49 mg/L, and the absolute bioavailability was 27." | 1.38 | Silicone adhesive, a better matrix for tolterodine patches-a research based on in vitro/in vivo studies. ( Chen, Y; Fang, L; Li, C; Liu, C; Liu, J; Mu, L; Sun, L; Wang, Z; Xi, H, 2012) |
| " Pharmacokinetic parameters were estimated from measurements of the concentration of imidafenacin in serum, the bladder, and the submaxillary gland by liquid chromatography-mass spectrometry/mass spectrometry." | 1.37 | Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder. ( Fukata, A; Ito, Y; Nakamura, M; Ogoda, M; Seki, M; Yamada, S, 2011) |
| "A 66-year-old female presented with memory loss secondary to the administration of oxybutynin, which resulted in medication nonadherence." | 1.36 | Medication nonadherence secondary to drug-induced memory loss. ( Barnes, CL; Clinard, VB; Nye, AM, 2010) |
| "Forty six patients with symptoms of overactive bladder, i." | 1.36 | In women with urinary incontinence how necessary is cystometry? ( Saleem, A, 2010) |
| "Oxybutynin chloride has been effectively used for treating overactive bladder syndrome for more than three decades." | 1.35 | The evolution of transdermal therapy for overactive bladder. ( Sand, PK, 2009) |
| "Oxybutynin-TDS was efficacious in spinal cord injury patients with neurogenic detrusor overactivity and was well tolerated at up to 3 times the standard dose." | 1.35 | Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. ( Foote, JE; Kennelly, MJ; Lemack, GE; Trop, CS, 2009) |
| "Propiverine was better tolerated than oxybutynin, having fewer adverse drug reactions (9." | 1.35 | Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study. ( Alloussi, S; Bock, P; Domurath, B; Henne, T; Körner, I; Madersbacher, H; Mürtz, G; Niedeggen, A; Nounla, J; Pannek, J; Schulte-Baukloh, H; Schultz-Lampel, D; Strugala, G, 2009) |
| "Oxybutynin chloride is an antispasmodic, anticholinergic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency." | 1.34 | Adsorptive stripping voltammetric behavior and determination of anticholinergic agent oxybutynin chloride on a mercury electrode. ( Jadon, N; Jain, R; Radhapyari, K, 2007) |
| "Overactive bladder is commonly treated with oral anticholinergic drugs such as oxybutynin chloride." | 1.33 | Transdermal oxybutynin for overactive bladder. ( Davila, GW; Dmochowski, RR; Starkman, JS, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 65 (35.33) | 29.6817 |
| 2010's | 104 (56.52) | 24.3611 |
| 2020's | 15 (8.15) | 2.80 |
| Authors | Studies |
|---|---|
| Sinha, S | 1 |
| Gupta, S | 1 |
| Malhotra, S | 1 |
| Krishna, NS | 1 |
| Meru, AV | 1 |
| Babu, V | 1 |
| Bansal, V | 1 |
| Garg, M | 1 |
| Kumar, N | 1 |
| Chugh, A | 1 |
| Ray, A | 1 |
| Matta, R | 1 |
| Gomes, T | 1 |
| Juurlink, D | 1 |
| Jarvi, K | 1 |
| Herschorn, S | 3 |
| Nam, RK | 1 |
| Marthi, S | 1 |
| Pomerantz, MA | 1 |
| Mernan, AJ | 1 |
| Berlow, YA | 1 |
| Sheng, Y | 1 |
| Zhang, S | 1 |
| Ling, J | 1 |
| Hu, C | 1 |
| Zhang, Z | 1 |
| Lv, H | 1 |
| Welk, B | 2 |
| Kitta, T | 2 |
| Darekar, A | 2 |
| Malhotra, B | 3 |
| Shahin, MH | 2 |
| Jones, P | 2 |
| Lindsay, M | 2 |
| Mallen, S | 2 |
| Nieto, A | 2 |
| Crook, TJ | 2 |
| Dengler, KL | 1 |
| High, RA | 1 |
| Moga, DC | 1 |
| Zillioux, J | 1 |
| Wagg, A | 3 |
| DuBeau, CE | 1 |
| Ackenbom, MF | 1 |
| Alperin, M | 1 |
| Dumoulin, C | 1 |
| Birder, LA | 1 |
| Mazloomdoost, D | 1 |
| Lai, HH | 1 |
| Sung, VW | 1 |
| Gray, SL | 1 |
| Sanses, TVD | 1 |
| Akkoç, Y | 1 |
| Bardak, AN | 1 |
| Yıldız, N | 1 |
| Özlü, A | 1 |
| Erhan, B | 1 |
| Yürü, B | 1 |
| Öztekin, SNS | 1 |
| Türkoğlu, MB | 1 |
| Paker, N | 1 |
| Yumuşakhuylu, Y | 1 |
| Canbaz Kabay, S | 1 |
| Ekmekçi, Ö | 1 |
| Elbi, H | 1 |
| Yüceyar, AN | 1 |
| Son, HS | 1 |
| Moon, SY | 1 |
| Kwon, J | 1 |
| Kim, JH | 1 |
| Ganguly, A | 1 |
| Tyagi, S | 1 |
| Chermansky, C | 1 |
| Kanai, A | 1 |
| Beckel, J | 1 |
| Hashimoto, M | 1 |
| Cho, KJ | 1 |
| Chancellor, M | 1 |
| Kaufman, J | 1 |
| Yoshimura, N | 1 |
| Tyagi, P | 1 |
| Raisin, G | 1 |
| Dothan, D | 1 |
| Perez, D | 1 |
| Ala-Adin, N | 1 |
| Kafka, I | 1 |
| Shenfeld, O | 1 |
| Hatumi, S | 1 |
| Malchi, N | 1 |
| Gordon, A | 1 |
| Touitou, D | 1 |
| Moldwin, R | 1 |
| Nassar, T | 1 |
| Chertin, B | 1 |
| Krunal Vishavadia, KV | 1 |
| Sandip Solanki, SS | 1 |
| Hiren Prajapati, HP | 1 |
| Madhu Sharma, MS | 1 |
| Zonić-Imamović, M | 1 |
| Imamović, S | 1 |
| Čičkušić, A | 1 |
| Delalić, A | 1 |
| Hodžić, R | 1 |
| Imamović, M | 1 |
| Rangganata, E | 1 |
| Widia, F | 1 |
| Rahardjo, HE | 1 |
| Suzuki, T | 2 |
| Minagawa, T | 1 |
| Saito, T | 1 |
| Nakagawa, T | 1 |
| Furuhata, M | 1 |
| Hosaka, K | 1 |
| Ogawa, T | 1 |
| Ishizuka, O | 2 |
| Richardson, K | 1 |
| Panicker, JN | 1 |
| Shabir, H | 1 |
| Hashemi, S | 2 |
| Al-Rufayie, M | 1 |
| Adelowo, T | 1 |
| Riaz, U | 1 |
| Ullah, U | 1 |
| Alam, B | 1 |
| Anwar, M | 1 |
| de Preux, L | 1 |
| Lua, LL | 1 |
| Pathak, P | 1 |
| Dandolu, V | 1 |
| Barroso, U | 1 |
| Vozmediano-Chicharro, R | 1 |
| Blasco Hernández, P | 1 |
| Madurga-Patuel, B | 1 |
| Nazir, J | 2 |
| Kelleher, C | 2 |
| Aballéa, S | 1 |
| Maman, K | 1 |
| Hakimi, Z | 1 |
| Mankowski, C | 1 |
| Odeyemi, I | 1 |
| Marcelissen, T | 1 |
| Rashid, T | 1 |
| Antunes Lopes, T | 1 |
| Delongchamps, NB | 1 |
| Geavlete, B | 1 |
| Rieken, M | 1 |
| Cornu, JN | 2 |
| Rahnama'i, MS | 1 |
| Snedecor, SJ | 1 |
| Merino Salas, S | 2 |
| Ferreira, RS | 1 |
| D'Ancona, CAL | 1 |
| Oelke, M | 1 |
| Carneiro, MR | 1 |
| Müller-Arteaga, C | 2 |
| Batista-Miranda, JE | 1 |
| Zubiaur Libano, C | 1 |
| El Khoury Moreno, R | 1 |
| Morales Solchaga, G | 1 |
| Casas Nebra, J | 1 |
| Leva Vallejo, M | 1 |
| Gonzalez Garcia, O | 1 |
| Errando-Smet, C | 2 |
| Arlandis-Guzman, S | 1 |
| Herbison, P | 1 |
| McKenzie, JE | 1 |
| Cetinel, B | 1 |
| Onal, B | 1 |
| Gultekin, MH | 1 |
| Guzelsoy, M | 1 |
| Turegun, FA | 1 |
| Dincer, M | 1 |
| Sacomani, CAR | 1 |
| Almeida, FG | 1 |
| Silvinato, A | 1 |
| Bernardo, WM | 1 |
| Milsom, I | 1 |
| Schiotz, HA | 1 |
| Svensson, M | 1 |
| Kilany, S | 1 |
| Hansson, F | 1 |
| Dale, M | 2 |
| Tretter, R | 2 |
| Stow, B | 2 |
| Compion, G | 2 |
| Finazzi-Agrò, E | 2 |
| Topazio, L | 1 |
| Perugia, C | 1 |
| Lombardi, G | 1 |
| Finita Celso, M | 1 |
| De Nunzio, C | 1 |
| Del Popolo, G | 2 |
| Souto, SC | 1 |
| Reis, LO | 2 |
| Palma, T | 1 |
| Palma, P | 1 |
| Denardi, F | 1 |
| Rittig, N | 1 |
| Hagstroem, S | 1 |
| Mahler, B | 1 |
| Kamperis, K | 1 |
| Siggaard, C | 1 |
| Mikkelsen, MM | 1 |
| Bower, WF | 1 |
| Djurhuus, JC | 1 |
| Rittig, S | 1 |
| van Gool, JD | 3 |
| de Jong, TP | 3 |
| Winkler-Seinstra, P | 1 |
| Tamminen-Möbius, T | 1 |
| Lax, H | 2 |
| Hirche, H | 3 |
| Nijman, RJ | 2 |
| Hjälmås, K | 1 |
| Jodal, U | 1 |
| Bachmann, H | 1 |
| Hoebeke, P | 2 |
| Walle, JV | 1 |
| Misselwitz, J | 1 |
| John, U | 1 |
| Bael, A | 2 |
| Babaoglu, M | 1 |
| Zumrutbas, AE | 1 |
| Acar, IC | 1 |
| Hatip, FB | 1 |
| Kucukatay, V | 1 |
| Eskicorapci, S | 1 |
| Aybek, Z | 1 |
| Ciftci, I | 1 |
| Arslan, D | 1 |
| Peru, H | 1 |
| Cimen, D | 1 |
| Oran, B | 1 |
| Gunduz, M | 1 |
| Hart, WM | 1 |
| Abrams, P | 1 |
| Munro, V | 1 |
| Retsa, P | 1 |
| Tuğcu-Demiröz, F | 1 |
| Acartürk, F | 1 |
| Erdoğan, D | 1 |
| Akino, H | 1 |
| Namiki, M | 1 |
| Suzuki, K | 2 |
| Fuse, H | 1 |
| Kitagawa, Y | 1 |
| Miyazawa, K | 1 |
| Fujiuchi, Y | 1 |
| Yokoyama, O | 2 |
| Gittelman, M | 1 |
| Weiss, H | 1 |
| Seidman, L | 1 |
| Yamaguchi, O | 3 |
| Uchida, E | 2 |
| Higo, N | 3 |
| Minami, H | 3 |
| Kobayashi, S | 2 |
| Sato, H | 2 |
| Rantell, A | 1 |
| Cardozo, L | 6 |
| Srikrishna, S | 4 |
| Humblet, M | 1 |
| Verpoorten, C | 1 |
| Christiaens, MH | 1 |
| Jansen, K | 1 |
| Buyse, G | 1 |
| Gleason, JM | 1 |
| Daniels, C | 1 |
| Williams, K | 1 |
| Varghese, A | 1 |
| Koyle, MA | 1 |
| Bägli, DJ | 1 |
| Pippi Salle, JL | 1 |
| Lorenzo, AJ | 1 |
| Kapoor, H | 1 |
| Gupta, E | 1 |
| Sood, A | 1 |
| Hadiji, N | 1 |
| Previnaire, JG | 1 |
| Benbouzid, R | 1 |
| Robain, G | 1 |
| Leblond, C | 1 |
| Mieusset, R | 1 |
| Enjalbert, M | 1 |
| Soler, JM | 1 |
| Kosilov, KV | 1 |
| Loparev, SA | 1 |
| Krasnykh, MA | 1 |
| Kosilova, LV | 1 |
| Álvares, RA | 1 |
| Araújo, ID | 1 |
| Sanches, MD | 1 |
| Jafarabadi, M | 2 |
| Jafarabadi, L | 1 |
| Shariat, M | 1 |
| Rabie Salehi, G | 1 |
| Haghollahi, F | 2 |
| Rashidi, BH | 1 |
| Esin, E | 1 |
| Ergen, A | 1 |
| Cankurtaran, M | 1 |
| Yavuz, BB | 1 |
| Halil, M | 1 |
| Ulger, Z | 1 |
| Yeşil, Y | 1 |
| Kuyumcu, ME | 1 |
| Ozcan, M | 1 |
| Cankurtaran, E | 1 |
| Ariogul, S | 1 |
| Ghanbari, Z | 1 |
| Nemati, M | 1 |
| Azimi Nekoo, E | 1 |
| Schröder, A | 2 |
| Albrecht, U | 1 |
| Schnitker, J | 1 |
| Reitz, A | 1 |
| Stein, R | 1 |
| Yamaguchi, A | 1 |
| Yoshida, M | 1 |
| Yamanishi, T | 1 |
| Seki, N | 1 |
| Takahashi, S | 1 |
| Masegi, Y | 1 |
| Quintiliano, F | 1 |
| Veiga, ML | 1 |
| Moraes, M | 1 |
| Cunha, C | 1 |
| de Oliveira, LF | 1 |
| Lordelo, P | 1 |
| Bastos Netto, JM | 1 |
| Barroso Júnior, U | 1 |
| Williams, NA | 1 |
| Lee, KM | 1 |
| Allender, CJ | 1 |
| Bowen, JL | 1 |
| Gumbleton, M | 1 |
| Harrah, T | 1 |
| Raja, A | 1 |
| Joshi, HB | 1 |
| Gurocak, S | 1 |
| Konac, E | 1 |
| Ure, I | 1 |
| Senol, C | 1 |
| Onen, IH | 1 |
| Sozen, S | 1 |
| Menevse, A | 1 |
| Salinas-Casado, J | 1 |
| Esteban-Fuertes, M | 1 |
| Serrano, O | 1 |
| Galván, J | 1 |
| McFerren, SC | 1 |
| Gomelsky, A | 2 |
| Rajabalaya, R | 2 |
| David, SR | 2 |
| Chellian, J | 2 |
| Xin Yun, G | 1 |
| Chakravarthi, S | 2 |
| Manríquez, V | 1 |
| Guzmán, R | 1 |
| Naser, M | 1 |
| Aguilera, A | 1 |
| Narvaez, S | 1 |
| Castro, A | 1 |
| Swift, S | 1 |
| Digesu, GA | 1 |
| Biardeau, X | 1 |
| Campeau, L | 1 |
| Corcos, J | 1 |
| Fahmy, A | 1 |
| Youssif, M | 1 |
| Rhashad, H | 1 |
| Mokhless, I | 1 |
| Mahfouz, W | 1 |
| Hsiao, SM | 1 |
| Lin, HH | 1 |
| Kuo, HC | 2 |
| Arlandis Guzmán, S | 1 |
| Lorenzo Gómez, MF | 1 |
| González López, R | 1 |
| Cambronero Santos, J | 1 |
| Gutiérrez Baños, JL | 1 |
| Sánchez Marcos, M | 1 |
| Ortiz Gamiz, A | 1 |
| Martínez Rodriguez, R | 1 |
| Olano Grasa, I | 1 |
| Wang, CC | 1 |
| Jiang, YH | 1 |
| Nalliah, S | 1 |
| Wg, P | 1 |
| Masten Singh, PK | 1 |
| Naidu, P | 1 |
| Lim, V | 1 |
| Ahamed, AA | 1 |
| Novara, G | 1 |
| Galfano, A | 1 |
| Secco, S | 1 |
| D'Elia, C | 1 |
| Cavalleri, S | 1 |
| Ficarra, V | 1 |
| Artibani, W | 2 |
| Sixt, R | 1 |
| Verhulst, J | 1 |
| Ellsworth, P | 1 |
| Caldamone, A | 1 |
| MacDiarmid, SA | 2 |
| Peters, KM | 1 |
| Chen, A | 2 |
| Armstrong, RB | 1 |
| Orman, C | 1 |
| Aquilina, JW | 1 |
| Nitti, VW | 1 |
| MacDiarmid, S | 5 |
| Sandage, BW | 1 |
| Malhotra, BK | 1 |
| Yamamoto, H | 1 |
| Kawano, PR | 1 |
| Balasteghin, KT | 1 |
| Padovani, CR | 1 |
| Amaro, JL | 2 |
| Madersbacher, H | 3 |
| Mürtz, G | 3 |
| Alloussi, S | 3 |
| Domurath, B | 1 |
| Henne, T | 1 |
| Körner, I | 1 |
| Niedeggen, A | 1 |
| Nounla, J | 1 |
| Pannek, J | 1 |
| Schulte-Baukloh, H | 1 |
| Schultz-Lampel, D | 2 |
| Bock, P | 2 |
| Strugala, G | 2 |
| Yoshinaga, Y | 1 |
| Staskin, DR | 5 |
| Dmochowski, RR | 6 |
| Sand, PK | 6 |
| Caramelli, KE | 3 |
| Thomas, H | 3 |
| Hoel, G | 4 |
| Baldwin, CM | 1 |
| Keating, GM | 1 |
| Wong, C | 1 |
| Duggan, P | 1 |
| Natalin, R | 1 |
| Alpendre, C | 1 |
| Ikari, LY | 1 |
| Prudente, A | 1 |
| D'Ancona, CA | 1 |
| Newman, DK | 5 |
| Chapple, CR | 2 |
| Rosenberg, MT | 3 |
| Brenes, FJ | 1 |
| Soljanik, I | 1 |
| Costantini, E | 1 |
| Lazzeri, M | 1 |
| Zát'ura, F | 1 |
| Vsetica, J | 1 |
| Abadías, M | 1 |
| Pavlík, I | 1 |
| Schraml, P | 1 |
| Brod'ák, M | 1 |
| Villoria, J | 1 |
| Sust, M | 1 |
| Pizzi, LT | 1 |
| Talati, A | 1 |
| Gemmen, E | 1 |
| Dahl, NV | 4 |
| Bunz, TJ | 1 |
| Wang, AC | 2 |
| Chen, MC | 2 |
| Kuo, WY | 1 |
| Lin, YH | 1 |
| Wang, YC | 1 |
| Lo, TS | 1 |
| Arruda, RM | 2 |
| Castro, R | 1 |
| Sartori, M | 1 |
| Girão, MJ | 2 |
| Kennelly, MJ | 1 |
| Lemack, GE | 1 |
| Foote, JE | 1 |
| Trop, CS | 1 |
| Cartwright, PC | 1 |
| Coplen, DE | 1 |
| Kogan, BA | 1 |
| Volinn, W | 1 |
| Finan, E | 1 |
| Bolduc, S | 1 |
| Moore, K | 1 |
| Lebel, S | 1 |
| Lamontagne, P | 1 |
| Hamel, M | 1 |
| Yang, SS | 1 |
| Jorgensen, TM | 1 |
| Van Meel, TD | 1 |
| De Wachter, S | 1 |
| Wyndaele, JJ | 3 |
| Robinson, D | 5 |
| Braun, R | 1 |
| Gerhardt, U | 1 |
| Heinrich, M | 1 |
| Hellmis, E | 1 |
| Horn, W | 1 |
| Marschall-Kehrel, D | 1 |
| Niklas, K | 1 |
| Raabe, M | 1 |
| Rössler, T | 1 |
| Seibt, B | 1 |
| Siemer, S | 1 |
| Walter, H | 1 |
| Wiedeking, B | 1 |
| Thorpe, A | 1 |
| Warner, J | 1 |
| Sidhu, M | 1 |
| Nye, AM | 1 |
| Clinard, VB | 1 |
| Barnes, CL | 1 |
| Stothers, L | 1 |
| Carlson, K | 1 |
| Egerdie, B | 1 |
| Gajewski, JB | 1 |
| Pommerville, P | 1 |
| Schulz, J | 1 |
| Radomski, S | 1 |
| Drutz, H | 1 |
| Barkin, J | 1 |
| Paradiso-Hardy, F | 1 |
| Saleem, A | 1 |
| Moon, HS | 1 |
| Lee, JW | 1 |
| Park, SY | 1 |
| Son, YW | 1 |
| Kim, YT | 1 |
| Salvatore, S | 2 |
| Yoshida, A | 1 |
| Maruyama, S | 2 |
| Fukumoto, D | 1 |
| Tsukada, H | 1 |
| Ito, Y | 2 |
| Yamada, S | 4 |
| Cartwright, R | 4 |
| Polido Júnior, A | 1 |
| Costa, JM | 1 |
| Munhoz, T | 1 |
| Sampaio, FJ | 1 |
| Cardoso, LE | 1 |
| Vicente, C | 1 |
| Piwko, C | 1 |
| Bödeker, RH | 1 |
| Neumeister, C | 1 |
| Zellner, M | 1 |
| Seki, M | 1 |
| Ogoda, M | 1 |
| Fukata, A | 1 |
| Nakamura, M | 1 |
| Keller, DL | 1 |
| Deng, YJ | 1 |
| Ma, G | 1 |
| Guo, YF | 1 |
| Ge, Z | 1 |
| Lu, RG | 1 |
| Wang, LX | 1 |
| Zhu, HB | 1 |
| Chen, CJ | 1 |
| Callegari, E | 1 |
| Bungay, PJ | 1 |
| Webster, R | 1 |
| Fenner, KS | 1 |
| Kempshall, S | 1 |
| LaPerle, JL | 1 |
| Michel, MC | 2 |
| Kay, GG | 2 |
| Thüroff, JW | 1 |
| Nelken, RS | 1 |
| Ozel, BZ | 1 |
| Leegant, AR | 1 |
| Felix, JC | 1 |
| Mishell, DR | 1 |
| Rudy, DC | 1 |
| Eckler, K | 1 |
| Davila, GW | 3 |
| Lucente, VR | 1 |
| Burgio, KL | 1 |
| Goode, PS | 1 |
| Johnson, TM | 1 |
| Hammontree, L | 1 |
| Ouslander, JG | 1 |
| Markland, AD | 1 |
| Colli, J | 1 |
| Vaughan, CP | 1 |
| Redden, DT | 1 |
| Yoo, DS | 1 |
| Han, JY | 1 |
| Lee, KS | 2 |
| Choo, MS | 2 |
| Madhuvrata, P | 1 |
| Cody, JD | 1 |
| Ellis, G | 1 |
| Herbison, GP | 1 |
| Hay-Smith, EJ | 1 |
| Hobaika, AB | 1 |
| Lee, YS | 1 |
| Kim, JC | 1 |
| Seo, JT | 1 |
| Lee, JZ | 1 |
| Aaron, LE | 1 |
| Morris, TJ | 1 |
| Jahshan, P | 1 |
| Reiz, JL | 1 |
| Asimakopoulos, AD | 1 |
| Cerruto, MA | 1 |
| La Martina, M | 1 |
| Carone, R | 1 |
| Schuler, V | 1 |
| Suter, K | 1 |
| Fürer, K | 1 |
| Eberli, D | 1 |
| Horst, M | 1 |
| Betschart, C | 1 |
| Brenneisen, R | 1 |
| Hamburger, M | 1 |
| Mennet, M | 1 |
| Schnelle, M | 1 |
| Simões-Wüst, AP | 1 |
| von Mandach, U | 1 |
| Leone Roberti Maggiore, U | 1 |
| Alessandri, F | 1 |
| Remorgida, V | 1 |
| Origoni, M | 1 |
| Candiani, M | 1 |
| Venturini, PL | 1 |
| Ferrero, S | 1 |
| Chin, HY | 1 |
| Lin, KC | 1 |
| Chiang, CH | 1 |
| Wang, CJ | 1 |
| McIlwain, M | 1 |
| Jirschele, K | 1 |
| Dede, H | 1 |
| Dolen, İ | 1 |
| Dede, FS | 1 |
| Sivaslioglu, AA | 1 |
| Kay, G | 1 |
| Crook, T | 1 |
| Rekeda, L | 1 |
| Lima, R | 1 |
| Ebinger, U | 1 |
| Arguinzoniz, M | 1 |
| Steel, M | 1 |
| Stöhrer, M | 1 |
| Kramer, G | 1 |
| Schnabel, F | 1 |
| Arnold, EP | 1 |
| Anderson, RU | 1 |
| Kell, S | 1 |
| Barada, JH | 1 |
| Serels, S | 1 |
| Goldberg, RP | 1 |
| Haferkamp, A | 1 |
| Hohenfellner, M | 1 |
| Diokno, A | 1 |
| Ingber, M | 1 |
| Starkman, JS | 1 |
| Hegde, SS | 1 |
| Jumadilova, Z | 1 |
| Varadharajan, S | 1 |
| Girase, P | 1 |
| Ollendorf, DA | 1 |
| Chih, SY | 1 |
| Fader, M | 1 |
| Glickman, S | 1 |
| Haggar, V | 1 |
| Barton, R | 1 |
| Brooks, R | 1 |
| Malone-Lee, J | 1 |
| Sand, P | 1 |
| Zinner, N | 1 |
| Newman, D | 1 |
| Lucente, V | 1 |
| Dmochowski, R | 1 |
| Ohtake, A | 1 |
| Saitoh, C | 1 |
| Yuyama, H | 1 |
| Ukai, M | 1 |
| Okutsu, H | 1 |
| Noguchi, Y | 1 |
| Hatanaka, T | 1 |
| Suzuki, M | 1 |
| Sato, S | 1 |
| Sasamata, M | 1 |
| Miyata, K | 1 |
| Oki, T | 1 |
| Kageyama, A | 1 |
| Takagi, Y | 1 |
| Uchida, S | 1 |
| Rogers, A | 1 |
| Vella, M | 1 |
| Cornel, EB | 1 |
| Schollhammer, M | 1 |
| Misery, L | 1 |
| Colli, E | 1 |
| Parazzini, F | 1 |
| Olivieri, L | 1 |
| Cipriani, S | 1 |
| Bertozzi, R | 1 |
| Meschia, M | 1 |
| Montorsi, F | 1 |
| Chancellor, MB | 1 |
| de Miguel, F | 1 |
| Shaw, GL | 1 |
| Patel, HR | 1 |
| Tallman, CT | 1 |
| Page, SA | 1 |
| Kafri, R | 1 |
| Shames, J | 1 |
| Raz, M | 1 |
| Katz-Leurer, M | 1 |
| Bolge, SC | 1 |
| McDonnell, DD | 1 |
| Wan, GJ | 1 |
| Jain, R | 1 |
| Radhapyari, K | 1 |
| Jadon, N | 1 |
| Schaefer, W | 1 |
| Minassian, VA | 1 |
| Ross, S | 1 |
| Sumabat, O | 1 |
| Lovatsis, D | 1 |
| Pascali, D | 1 |
| Al-Badr, A | 1 |
| Alarab, M | 1 |
| Drutz, HP | 1 |
| Ito, K | 1 |
| Iwami, A | 1 |
| Katsura, H | 1 |
| Ikeda, M | 1 |
| Polishuk, PV | 1 |
| Zinner, NR | 1 |
| Lam, S | 1 |
| Hilas, O | 1 |
| Hasuike, N | 1 |
| Sahai, A | 1 |
| Mallina, R | 1 |
| Dowson, C | 1 |
| Larner, T | 1 |
| Khan, MS | 1 |
| Castro, RA | 1 |
| Sousa, GC | 1 |
| Sartori, MG | 1 |
| Baracat, EC | 1 |
| D'Souza, AO | 1 |
| Smith, MJ | 1 |
| Miller, LA | 1 |
| Doyle, J | 1 |
| Ariely, R | 1 |
| Mun, CY | 1 |
| Scott, K | 1 |
| Padmanabhan, P | 1 |
| Liu, J | 1 |
| Wang, Z | 1 |
| Liu, C | 1 |
| Xi, H | 1 |
| Li, C | 1 |
| Chen, Y | 1 |
| Sun, L | 1 |
| Mu, L | 1 |
| Fang, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| To Explore the Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and Develop Its Urinary Biomarker[NCT04693897] | 400 participants (Anticipated) | Observational [Patient Registry] | 2021-03-01 | Not yet recruiting | |||
| Oxybutynin for Post-surgical Bladder Pain and Urgency[NCT03952299] | Phase 3 | 100 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | ||
| Comparison of the Efficacy of Transcutaneous Tibial Nerve Stimulation in Antimuscarinic Naive and Refractory Women With Idiopathic Overactive Bladder[NCT05668715] | 40 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | |||
| Transcutaneous Tibial Nerve Stimulation for Spinal Cord Injury Neurogenic Bladder[NCT04350359] | 120 participants (Anticipated) | Interventional | 2020-06-08 | Recruiting | |||
| The Use of Topical Oxybutynin 10% for Treating Primary Focal Hyperhidrosis-axillary, Palmar and Plantar.[NCT02973659] | 61 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Dosing With Oxybutynin Topical Gel to Treat the Symptoms of Overactive Bladder With a 14-Week Open-Label Safety Extension[NCT00350636] | Phase 3 | 789 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Prospective Randomized Evaluation of Peri-Ureteral and Intradetrusor Injection of Botulinum Toxin Type A for the Treatment of Ureteral Stent Related Pain and Irritative Voiding Symptoms[NCT02078895] | Phase 3 | 15 participants (Actual) | Interventional | 2014-02-28 | Terminated (stopped due to The study was terminated due to low enrollment) | ||
| A Multi-center, Open-label, Dose-titration Pilot Study Evaluating the Efficacy and Safety of Oxybutynin Transdermal Systems in Patients With Neurogenic Bladder Resulting From Spinal Cord Injury[NCT00224029] | Phase 4 | 24 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| A Two-part, Multicenter, Dose-titration Study Evaluating the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Oxybutynin Chloride 10% Gel for the Treatment of Detrusor Overactivity Associated With a Neurological Condition in Pediatric Patients[NCT01192568] | Phase 4 | 19 participants (Actual) | Interventional | 2011-05-02 | Active, not recruiting | ||
| A Multi-Center, Open-Label (OL), Active-Controlled, Dose-Titration Study Evaluating the Safety, Efficacy and PK of Oxybutynin Transdermal Systems in the Treatment of Detrusor Overactivity in Pediatric Patients[NCT00224016] | Phase 4 | 57 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| VECTOR: A Randomized Double-blind Study to Assess the Safety and Efficacy of Solifenacin (Vesicare®) in Comparison to Oxybutynin for Overactive Bladder Patients[NCT00431041] | Phase 4 | 132 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides[NCT02524769] | 27 participants (Actual) | Interventional | 2015-12-31 | Completed | |||
| Use of Biotene Moisturizing Mouth Spray for Xerostomia Associated With Oral Oxybutynin Use[NCT02522936] | Phase 4 | 0 participants (Actual) | Interventional | 2018-08-01 | Withdrawn (stopped due to Due to lack of funding and necessary personnel we determined that the study could not be done.) | ||
| Investigation of the Effect of the Female Urinary Microbiome on Incontinence[NCT02835846] | Phase 4 | 35 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Vaginal Estradiol vs Oral Beta-3 Agonist for Treatment of Overactive Bladder Syndrome: A Single-Therapy, Double-Blind, Randomized Controlled Trial[NCT05221021] | Phase 4 | 152 participants (Anticipated) | Interventional | 2022-10-01 | Recruiting | ||
| Behavioral Treatment of Overactive Bladder in Men[NCT01187498] | Phase 3 | 143 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks - a Single-center Study[NCT05557279] | Phase 4 | 40 participants (Anticipated) | Interventional | 2023-01-01 | Recruiting | ||
| The Effectiveness of Parassacral Transcutaneous Stimulation Compared to Tibial Transcutaneous Stimulation, Home Protocol and Behavioral Therapy in the Treatment of Female Hyperative Bladder: Randomized Clinical Trial[NCT04909047] | 120 participants (Anticipated) | Interventional | 2021-07-01 | Recruiting | |||
| Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers[NCT00752141] | Phase 1 | 153 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| A Double Blind, Randomized Four Way Cross Over Study to Compare the Effect of Fesoterodine 4mg and 8mg Once Daily and Oxybutynin 5mg Twice Daily After Steady State Dosing Versus Placebo on Cognitive Function in Subjects With Overactive Bladder, Over the A[NCT02240459] | Phase 2 | 47 participants (Actual) | Interventional | 2016-08-31 | Completed | ||
| A Study to Compare the Cognitive Effect of Solifenacin 5mg Once-daily and Oxybutynin 5mg Twice-daily After Chronic Dosing Versus Placebo in Subjects 75 Years and Over With Mild Cognitive Impairment - A Double-blind, Randomized, Multi-center Study[NCT01126424] | Phase 4 | 26 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Randomized Cross-Over Study of Fesoterodine on Urgency Episodes in Parkinson's Disease Population[NCT02385500] | Phase 4 | 5 participants (Actual) | Interventional | 2016-09-30 | Terminated (stopped due to Insufficient or untimely patient recruitment) | ||
| Multicenter Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin TDS (MATRIX)[NCT00224146] | Phase 4 | 2,878 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Retrospective Evaluation of Long Term Use of Oxybutynin in the Pharmacological Treatment of Primary Hyperhidrosis[NCT01956591] | 1,100 participants (Actual) | Observational | 2007-09-30 | Completed | |||
| Overactive Bladder Education[NCT02505607] | 22 participants (Actual) | Interventional | 2015-07-31 | Terminated (stopped due to feasibility issues) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of daily urinary voids (NCT00350636)
Timeframe: Baseline
| Intervention | Number of urinary episodes (Mean) |
|---|---|
| Oxybutynin Topical Gel | 12.4 |
| Placebo Topical Gel | 12.2 |
Average number of daily incontinence episodes at baseline (NCT00350636)
Timeframe: Baseline
| Intervention | Number of episodes (Mean) |
|---|---|
| Oxybutynin Topical Gel | 5.4 |
| Placebo Topical Gel | 5.4 |
Baseline average urine void volume (NCT00350636)
Timeframe: Baseline
| Intervention | mL (Mean) |
|---|---|
| Oxybutynin Topical Gel | 163.4 |
| Placebo Topical Gel | 167.9 |
Change from Baseline to Week 12 in average daily number of incontinence episodes (NCT00350636)
Timeframe: Baseline to Week 12
| Intervention | Number of episodes (Mean) |
|---|---|
| Oxybutynin Topical Gel | -3.0 |
| Placebo Topical Gel | -2.5 |
Change from baseline in average daily urinary frequency (NCT00350636)
Timeframe: Baseline to 12 weeks
| Intervention | Number of urinary episodes (Mean) |
|---|---|
| Oxybutynin Topical Gel | -2.7 |
| Placebo Topical Gel | -2.0 |
Change from baseline to Week 12 in average urine void volume (NCT00350636)
Timeframe: Change from Baseline to Week 12
| Intervention | mL (Mean) |
|---|---|
| Oxybutynin Topical Gel | 21.0 |
| Placebo Topical Gel | 3.8 |
Baseline in number of daily catheterizations without leaking per day as recorded in a 3-day urinary diary. (NCT00224029)
Timeframe: 8 weeks
| Intervention | Number of Dry Catheterizations per Day (Mean) | |
|---|---|---|
| Baseline at Week 0 | Change from baseline at Week 8 | |
| Oxybutynin Transdermal System | 2.4 | 1.5 |
Change from baseline in average volume of urine collected by catheterization (NCT00224016)
Timeframe: 14 weeks
| Intervention | mL (Mean) | |
|---|---|---|
| Baseline Catheterization Volume | Change from Baseline in Cath Volume | |
| Oral Oxybutynin | 114.0 | 52.4 |
| Oxybutynin TDS | 95.3 | 30.0 |
Percentage of catherizations without leakage (NCT00224016)
Timeframe: 14 weeks
| Intervention | % of participants (Mean) | |
|---|---|---|
| Baseline % Catheterizations without leakage | Endpoint % Catheterizations without leakage | |
| Oral Oxybutynin | 38.1 | 72.6 |
| Oxybutynin TDS | 28.7 | 53.8 |
The number of subjects reporting incidence of dry mouth as an adverse event (AE) following direct questioning at each patient follow-up visit (NCT00431041)
Timeframe: 8 weeks
| Intervention | participants (Number) |
|---|---|
| Solifenacin | 24 |
| Oxybutynin IR | 53 |
"Subjects were instructed to complete the diary in the 3 day period immediately proceding the visit. Subjects recorded each micturition or instance of passing urine in the toliet.~The mean was calculated for each time point as the average of the day 1-3 measurements from the associated 3 day diary. Change from baseline was calculated as Week 8- Baseline." (NCT00431041)
Timeframe: Baseline and 8 Weeks
| Intervention | Micturitions per day (Mean) | ||
|---|---|---|---|
| Change in micturition frequency at 8 wks(N=52; 40) | Micturition frequency at Baseline (N=68; 64) | Micturition frequency at 8 weeks (N=52; 40) | |
| Oxybutynin IR | -3.1 | 12.5 | 9.0 |
| Solifenacin | -2.3 | 12.4 | 9.9 |
"Subjects were instructed to complete the diary in the 3 day period immediately preceding the visit. Subjects recorded each urgency episode or instance of strong desire to pass urine.~The mean was calculated for each time point as the average of the day 1-3 measurements from the associated 3 day diary. Change from Baseline was calculated as Week 8- Baseline." (NCT00431041)
Timeframe: Baseline and 8 weeks
| Intervention | urgency episodes per day (Mean) | ||
|---|---|---|---|
| Change in urgency episodes at 8 weeks (N=52; 40) | Urgency episodes at Baseline (N= 68; 64) | Urgency episodes at 8 weeks (N=52; 40) | |
| Oxybutynin IR | -3.70 | 6.6 | 2.1 |
| Solifenacin | -2.65 | 6.3 | 3.8 |
"The number of subjects reporting dry mouth at each severity level when dry mouth was reported as an Adverse Event (AE).~Dry mouth severity was categorized as mild (relieved with fluid/hard candy), moderate (dry mouth and throat with no difficulty swallowing solid food/water) & severe (very dry mouth & throat, difficulty swallowing solid food without water)" (NCT00431041)
Timeframe: 8 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| Mild | Moderate | Severe | |
| Oxybutynin IR | 16 | 22 | 15 |
| Solifenacin | 18 | 3 | 3 |
OAB symptoms are measured using the Overactive Bladder Questionnaire (OAB-q). The OAB-q symptom score ranges from 0-100 with higher scores indicating greater symptom severity. A change score is calculated as the post-treatment score minus the pre-treatment score. (NCT02524769)
Timeframe: 0, 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Estrogen Arm | -23 |
The investigators will determine whether any change in OAB symptoms using the OAB-q before and after treatment is associated with the change in participants' AMP levels before and after treatment. AMP activity level is measured as bacterial growth inhibition in square millimeters normalized to the total peptide bond concentration. The OAB-q symptom score ranges from 0-100 with higher scores indicating greater symptom severity. (NCT02524769)
Timeframe: 0, 12 weeks
| Intervention | Spearman's rho (Number) |
|---|---|
| Estrogen Arm | 0.60 |
The relative abundance of Lactobacillus to total microbes per sample was measured before and after treatment. The within-participant change in relative abundance of Lactobacillus was calculated subtracting pre-treatment from post-treatment. (NCT02524769)
Timeframe: 0, 12 weeks
| Intervention | proportion of total microbes (Mean) |
|---|---|
| Estrogen Arm | 0.143 |
The investigators will compare participants' AMP levels before and after treatment. AMP activity level is measured as bacterial growth inhibition in square millimeters normalized to the total peptide bond concentration. Change is calculated as the post-treatment AMP level minus the pre-treatment AMP level. (NCT02524769)
Timeframe: 0, 12 weeks
| Intervention | square millimeters per unit (Median) |
|---|---|
| Estrogen Arm | -0.11 |
The investigators will determine whether change in OAB symptoms using the OAB-q before and after treatment is associated with the change in participants' relative abundance of Lactobacillus before and after treatment. The OAB-q symptom score ranges from 0-100 with higher scores indicating greater symptom severity. (NCT02524769)
Timeframe: 0, 12 weeks
| Intervention | Spearman's rho (Number) |
|---|---|
| Estrogen Arm | -0.59 |
OAB symptoms are measured using the Overactive Bladder Questionnaire (OAB-q). The OAB-q symptom score ranges from 0-100 with higher scores indicating greater symptom severity. A change score is calculated as the post-treatment score minus the pre-treatment score. (NCT02835846)
Timeframe: 0, 12 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Estrogen Arm | -21 |
The investigators will determine whether any change in OAB symptoms using the OAB-q before and after treatment is associated with the change in participants' AMP levels before and after treatment. (NCT02835846)
Timeframe: 0, 12 weeks
| Intervention | Spearman's rho (Number) |
|---|---|
| Estrogen Arm | -1 |
The relative abundance of Lactobacillus to total microbes per sample was measured before and after treatment. The within-participant change in relative abundance of Lactobacillus was calculated subtracting pre-treatment from post-treatment. (NCT02835846)
Timeframe: 0, 12 weeks
| Intervention | proportion of total microbes (Mean) |
|---|---|
| Estrogen Arm | 0.275 |
The investigators will compare participants' AMP activity levels before and after treatment. AMP activity level is measured as the diffusion of AMPs in bacterial agar from the center of the well to which the patient's purified biological sample is applied. The diffusion of AMPs in the agar results in the killing of bacteria and a clearing around the well. This clearing of bacterial growth is measured in square millimeters and then normalized to the total peptide concentration. Change is calculated as the post-treatment AMP activity level minus the pre-treatment AMP activity level. (NCT02835846)
Timeframe: 0, 12 weeks
| Intervention | normalized bacterial growth inhibition (Median) |
|---|---|
| Estrogen Arm | 0.14 |
The investigators will determine whether change in OAB symptoms using the OAB-q before and after treatment is associated with the change in participants' relative abundance of Lactobacillus before and after treatment. The OAB-q symptom score ranges from 0-100 with higher scores indicating greater symptom severity. (NCT02835846)
Timeframe: 0, 12 weeks
| Intervention | Spearman's rho (Number) |
|---|---|
| Estrogen Arm | -0.32 |
Mean voiding frequency per 24 hours derived from 7-day bladder dairy (NCT01187498)
Timeframe: post-treatment (week 8)
| Intervention | voids per 24-hour day (Mean) |
|---|---|
| Behavioral Training | 9.1 |
| Drug Therapy | 9.5 |
Change in frequency of nocturia episodes based on 7-day bladder diary (NCT01187498)
Timeframe: baseline to post-treatment (week 8)
| Intervention | nocturia episodes per night (Mean) |
|---|---|
| Behavioral Training | -0.70 |
| Drug Therapy | -.32 |
"Indevus Urgency Severity Scale incorporated into the 7-day bladder diary. Scores for urgency severity ranged from 0 to 3:~0: None-no urgency~Mild-awareness of urgency, but is easily tolerated.~Moderate-enough urgency discomfort that it interferes with or shortens usual activity~Severe-extreme urgency discomfort that abruptly stops all activities or tasks." (NCT01187498)
Timeframe: baseline to post-treatment (week 8)
| Intervention | Score on scale (Mean) |
|---|---|
| Behavioral Training | .04 |
| Drug Therapy | -.15 |
Change in score on American Urological Association (AUA) Symptom Index (baseline to week 8). The index measures lower urinary tract symptoms. Scores range from 0 to 35, with higher scores indicating worse symptoms. (NCT01187498)
Timeframe: baseline to post-treatment (week 8)
| Intervention | Scores on the scale (Mean) |
|---|---|
| Behavioral Training | 3.4 |
| Drug Therapy | 3.2 |
"Patient response to Do you wish to receive another form of treatment? (yes)" (NCT01187498)
Timeframe: post-treatment (week 8)
| Intervention | participants (Number) |
|---|---|
| Behavioral Training | 18 |
| Drug Therapy | 30 |
Percent change in frequency of urge incontinence episodes based on 7-day bladder diary. Percent change was calculated as ([frequency at baseline] - [frequency at 8 weeks]) / (frequency at baseline). (NCT01187498)
Timeframe: baseline to post-treatment (week 8)
| Intervention | Percent change in episodes per week (Mean) |
|---|---|
| Behavioral Training | 87.2 |
| Drug Therapy | 75.6 |
"Patient global perception of improvement (much better to much worse)" (NCT01187498)
Timeframe: post-treatment (week 8)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Much better | Better | About the same | Worse | Much worse | |
| Behavioral Training | 23 | 30 | 10 | 0 | 0 |
| Drug Therapy | 18 | 34 | 7 | 1 | 0 |
"Patient global rating of activity restriction (not at all to all the time)" (NCT01187498)
Timeframe: post-treatment (week 8)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Not at all | Slightly | Some of the time | All the time | |
| Behavioral Training | 29 | 19 | 11 | 4 |
| Drug Therapy | 31 | 15 | 13 | 1 |
"Patient global rating of how bothersome their side effects were (no side effects to extremely bothersome)" (NCT01187498)
Timeframe: post-treatment (week 8)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| No side effects | Not at all bothersome | A Little | Somewhat | Extremely | |
| Behavioral Training | 23 | 16 | 16 | 7 | 1 |
| Drug Therapy | 11 | 13 | 19 | 13 | 4 |
"Patient report of how disturbed they were by symptoms (not at all to extremely)" (NCT01187498)
Timeframe: post-treatment (week 8)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Not at all | Slightly | Somewhat | All the time | |
| Behavioral Training | 19 | 30 | 14 | 0 |
| Drug Therapy | 17 | 35 | 7 | 1 |
"Patient global rating of satisfaction with progress in treatment (completely satisfied to very dissatisfied)" (NCT01187498)
Timeframe: post-treatment (week 8)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Completely satisfied | Somewhat satisfied | Somewhat dissatisfied | Very Dissatisfied | |
| Behavioral Training | 36 | 25 | 2 | 0 |
| Drug Therapy | 25 | 33 | 2 | 0 |
Cognitive effects were assessed using a computerized assessment system at time points close to the predicted time of maximum plasma concentration for solifenacin and oxybutynin. For continuity of attention, the number of correct responses (out of 50) for choice reaction time was added to the total number of targets correctly identified (out of 45) digit vigilance minus the number of false alarms (total score of -45 to 95). A high score reflects someone able to keep his/her mind on a single task for a prolonged period. A negative change from baseline reflects impairment compared to baseline. (NCT01126424)
Timeframe: Assessed at each treatment period baseline visit (the day prior to the first dose of each treatment; Days -1, 42, 84) and at the end of each treatment period (Days 21, 63 and 105). At each visit, tests were performed at 2 and 6 hours post-dose.
| Intervention | Scores on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline at 2 hours [Oxybutynin Tmax] | Change from Baseline at 2 hours | Baseline at 6 hours [Solifenacin Tmax] | Change from Baseline at 6 hours | |
| Oxybutynin | 91.300 | 0.150 | 91.901 | 0.100 |
| Placebo | 91.364 | 0.909 | 91.728 | -0.045 |
| Solifenacin | 91.591 | 0.545 | 91.228 | -0.318 |
Cognitive effects were assessed at the end of each treatment period using a computerized assessment system at time points close to the predicted time to attain maximum plasma concentration (Tmax) for solifenacin (6 hours) and oxybutynin (2 hours). Power of attention is calculated from the sum of three cognitive function speed tests: Simple Reaction Time, Choice Reaction Time and the Speed of Detections in Digit Vigilance task. A low score reflects a fast reaction time and a high intensity of concentration. A positive change from baseline reflects impairment compared to the baseline assessment. (NCT01126424)
Timeframe: Assessed at each treatment period baseline visit (the day prior to the first dose of each treatment; Days -1, 42, 84) and at the end of each treatment period (Days 21, 63 and 105). At each visit, tests were performed at 2 and 6 hours post-dose.
| Intervention | msec (Mean) | |||
|---|---|---|---|---|
| Baseline at 2 hours [Oxybutynin Tmax] | Change from Baseline at 2 hours | Baseline at 6 hours [Solifenacin Tmax] | Change from Baseline at 6 hours | |
| Oxybutynin | 1423.38 | 17.81 | 1405.41 | -0.74 |
| Placebo | 1401.21 | 1.99 | 1393.98 | 11.77 |
| Solifenacin | 1413.67 | -5.86 | 1421.80 | -14.80 |
Cognitive effects were assessed at the end of each treatment period using a computerized assessment system at time points close to the predicted time of maximum plasma concentration for solifenacin and oxybutynin. Quality of episodic secondary memory is calculated from the sum of 4 tests: Immediate and delayed word recall, and word and picture recognition, and ranges from -200 to 400. A high score reflects a good ability to store, hold and retrieve information of an episodic nature (i.e. an event or a name) and a negative change from baseline reflects impairment compared to baseline. (NCT01126424)
Timeframe: Assessed at each treatment period baseline visit (the day prior to the first dose of each treatment; Days -1, 42, 84) and at the end of each treatment period (Days 21, 63 and 105). At each visit, tests were performed at 2 and 6 hours post-dose.
| Intervention | Scores on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline at 2 hours [Oxybutynin Tmax] | Change from Baseline at 2 hours | Baseline at 6 hours [Solifenacin Tmax] | Change from Baseline at 6 hours | |
| Oxybutynin | 107.666333 | -0.917833 | 104.917167 | -3.502000 |
| Placebo | 110.000152 | 0.531515 | 106.515000 | 1.589394 |
| Solifenacin | 111.893636 | -3.788636 | 101.363485 | 7.728182 |
Cognitive effects were assessed at the end of each treatment period using a computerized assessment system at time points close to the predicted time to attain maximum plasma concentration (Tmax) for solifenacin (6 hours) and oxybutynin (2 hours). Quality of working memory is calculated from the sum of two cognitive function sensitivity tests: Numeric Working Memory Sensitivity and Spatial Working Memory Sensitivity, and ranges from -2 to 2. A higher score reflects a good working memory and a negative change from baseline reflects impairment compared to the baseline assessment. (NCT01126424)
Timeframe: Assessed at each treatment period baseline visit (the day prior to the first dose of each treatment; Days -1, 42, 84) and at the end of each treatment period (Days 21, 63 and 105). At each visit, tests were performed at 2 and 6 hours post-dose.
| Intervention | Scores on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline at 2 hours [Oxybutynin Tmax] | Change from Baseline at 2 hours | Baseline at 6 hours [Solifenacin Tmax] | Change from Baseline at 6 hours | |
| Oxybutynin | 1.7251 | -0.0043 | 1.6441 | 0.0633 |
| Placebo | 1.7087 | 0.0492 | 1.7548 | 0.0047 |
| Solifenacin | 1.7921 | -0.0867 | 1.6666 | 0.0580 |
Cognitive effects were assessed at the end of each treatment period using a computerized assessment system at time points close to the predicted time to attain maximum plasma concentration for solifenacin and oxybutynin. Speed of Memory was calculated from the sum of 4 cognitive function speed tests: numeric and spatial working memory and word and picture recognition. A low score reflects that a person is able to recall a name, a face or any other item fast from the episodic secondary memory; a positive change from baseline reflects impairment compared to baseline. (NCT01126424)
Timeframe: Assessed at each treatment period baseline visit (the day prior to the first dose of each treatment; Days -1, 42, 84) and at the end of each treatment period (Days 21, 63 and 105). At each visit, tests were performed at 2 and 6 hours post-dose.
| Intervention | msec (Mean) | |||
|---|---|---|---|---|
| Baseline at 2 hours [Oxybutynin Tmax] | Change from Baseline at 2 hours | Baseline at 6 hours [Solifenacin Tmax] | Change from Baseline at 6 hours | |
| Oxybutynin | 4545.75 | -11.56 | 4606.51 | -118.14 |
| Placebo | 4741.30 | -240.62 | 4655.29 | -126.04 |
| Solifenacin | 4505.96 | 24.09 | 4496.65 | -149.79 |
"The postural stability test measures the ability to stand upright without moving, and was assessed at the end of each treatment period using a computerized assessment system at time points close to the predicted time to attain maximum plasma concentration for solifenacin and oxybutynin. Using apparatus modeled on the Wright Ataxia-meter, a cord from the meter is attached to the patient who is required to stand as still as possible with feet apart and eyes closed for 1 minute.~The amount of sway is expressed as the total angular movement, summed regardless of sign, in the antero-posterior plane and calibrated in units of one-third degree of angle of sway. Wright (1971) described a range of 20-30 units as a normal range for adults with eyes wide open, increasing by 50 to 100% with eyes shut." (NCT01126424)
Timeframe: Assessed at each treatment period baseline visit (the day prior to the first dose of each treatment; Days -1, 42, 84) and at the end of each treatment period (Days 21, 63 and 105). At each visit, tests were performed at 2 and 6 hours post-dose.
| Intervention | 1/3 degree of angle of sway (Mean) | |||
|---|---|---|---|---|
| Baseline at 2 hours [Oxybutynin Tmax] | Change from Baseline at 2 hours | Baseline at 6 hours [Solifenacin Tmax] | Change from Baseline at 6 hours | |
| Oxybutynin | 36.2 | 2.7 | 38.9 | 0.7 |
| Placebo | 37.5 | 0.4 | 40.0 | -0.1 |
| Solifenacin | 37.7 | 5.2 | 37.7 | 9.9 |
44 reviews available for oxybutynin and Bladder, Overactive
| Article | Year |
|---|---|
The Differential Risk of Mortality Among Users of Overactive Bladder Anticholinergic Medications and β3 Agonists.
Topics: Aged; Cholinergic Antagonists; Humans; Mandelic Acids; Urinary Bladder, Overactive | 2023 |
Overactive Bladder and Cognitive Impairment: The American Urogynecologic Society and Pelvic Floor Disorders Research Foundation State-of-the-Science Conference Summary Report.
Topics: Aged; Cholinergic Antagonists; Cognitive Dysfunction; Female; Humans; Mechanotransduction, Cellular; | 2023 |
Treating Lower Urinary Tract Symptoms in Older Adults: Intravesical Options.
Topics: Administration, Intravesical; Aged; Botulinum Toxins, Type A; Drug-Related Side Effects and Adverse | 2023 |
Effect of Antimuscarinic Drugs on Cognitive Functions in the Management of Overactive Bladder in Elderly.
Topics: Aged; Benzofurans; Cognition Disorders; Humans; Mandelic Acids; Mental Status and Dementia Tests; Mu | 2020 |
The cognitive effect of anticholinergics for patients with overactive bladder.
Topics: Benzhydryl Compounds; Benzofurans; Cholinergic Antagonists; Cognition; Cognitive Dysfunction; Dement | 2021 |
Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.
Topics: Benzhydryl Compounds; Benzilates; Humans; Mandelic Acids; Muscarinic Antagonists; Network Meta-Analy | 2018 |
Oral Pharmacologic Management of Overactive Bladder Syndrome: Where Do We Stand?
Topics: Acetanilides; Administration, Oral; Adrenergic beta-3 Receptor Agonists; Aged; Case-Control Studies; | 2019 |
Review of Economic Value Drivers of the Treatment of Overactive Bladder.
Topics: Botulinum Toxins; Canada; Cost-Benefit Analysis; Health Care Costs; Health Status; Humans; Mandelic | 2018 |
Which anticholinergic is best for people with overactive bladders? A network meta-analysis.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Cholinergic Antagonists; Humans; Imidazoles; Mandelic | 2019 |
Fesoterodine fumarate and the oxybutynin ring for the treatment of urinary incontinence in women.
Topics: Benzhydryl Compounds; Cholinergic Antagonists; Contraceptive Devices, Female; Drug Delivery Systems; | 2014 |
Chronic pelvic ischemia: etiology, pathogenesis, clinical presentation and management.
Topics: Aged; Animals; Atherosclerosis; Calcium; Cell Hypoxia; Chronic Pain; Disease Models, Animal; Estroge | 2014 |
The value of oxybutynin in transdermal patches for treating overactive bladder.
Topics: Humans; Mandelic Acids; Muscarinic Antagonists; Transdermal Patch; Urinary Bladder, Overactive | 2015 |
Treatment of Overactive Bladder in the Elderly Female: The Case for Trospium, Oxybutynin, Fesoterodine and Darifenacin.
Topics: Aged; Aging; Benzhydryl Compounds; Benzofurans; Blood-Brain Barrier; Cognition; Female; Humans; Mand | 2015 |
Comparison of efficacy and tolerability of pharmacological treatment for the overactive bladder in women: A network meta-analysis.
Topics: Dose-Response Relationship, Drug; Female; Humans; Mandelic Acids; Randomized Controlled Trials as To | 2017 |
A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder.
Topics: Benzhydryl Compounds; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; | 2008 |
[Multinational clinical trial in Japan and Korea on detrusitol].
Topics: Benzhydryl Compounds; Cresols; Double-Blind Method; Female; Humans; International Cooperation; Japan | 2009 |
Transdermal oxybutynin.
Topics: Administration, Cutaneous; Humans; Mandelic Acids; Muscarinic Antagonists; Urinary Bladder, Overacti | 2009 |
Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome.
Topics: Benzofurans; Drug Administration Schedule; Humans; Mandelic Acids; Multicenter Studies as Topic; Mus | 2009 |
Comparison between oxybutynin, functional electrical stimulation and pelvic floor training for treatment of detrusor overactivity in women: a review.
Topics: Combined Modality Therapy; Electric Stimulation Therapy; Exercise Therapy; Female; Humans; Mandelic | 2009 |
Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.
Topics: Administration, Cutaneous; Chemistry, Pharmaceutical; Clinical Trials, Phase III as Topic; Gels; Hum | 2009 |
Topical oxybutynin (Gelnique) for overactive bladder.
Topics: Administration, Topical; Animals; Constipation; Humans; Mandelic Acids; Randomized Controlled Trials | 2010 |
Oxybutynin topical and transdermal formulations: an update.
Topics: Administration, Cutaneous; Administration, Topical; Cholinergic Antagonists; Gels; Humans; Mandelic | 2010 |
New strategies for medical management of overactive bladder in children.
Topics: Benzhydryl Compounds; Benzilates; Botulinum Toxins; Child; Cresols; Humans; Mandelic Acids; Muscarin | 2010 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropano | 2012 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropano | 2012 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropano | 2012 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropano | 2012 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropano | 2012 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropano | 2012 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropano | 2012 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropano | 2012 |
Which anticholinergic drug for overactive bladder symptoms in adults.
Topics: Adult; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Humans; Mandelic Acids; Phenylpropano | 2012 |
Oxybutynin gel for the treatment of overactive bladder.
Topics: Administration, Cutaneous; Evidence-Based Medicine; Gels; Humans; Mandelic Acids; Muscarinic Antagon | 2012 |
An overview on mixed action drugs for the treatment of overactive bladder and detrusor overactivity.
Topics: Benzilates; Drug Administration Schedule; Female; Flavoxate; Humans; Male; Mandelic Acids; Muscarini | 2012 |
Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Chronic Disease; Cresols; Drug Combinations; Female; | 2012 |
Oxybutynin: past, present, and future.
Topics: Drug Administration Routes; Humans; Mandelic Acids; Muscarinic Antagonists; Urinary Bladder, Overact | 2013 |
The puzzle of overactive bladder: controversies, inconsistencies, and insights.
Topics: Animals; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Female; Humans; Mandelic Acids; Mus | 2006 |
[Intravesical treatment of overactive bladder syndrome].
Topics: Administration, Intravesical; Anesthetics, Local; Botulinum Toxins, Type A; Cholinergic Antagonists; | 2006 |
Oxybutynin in detrusor overactivity.
Topics: Humans; Mandelic Acids; Muscarinic Antagonists; Urinary Bladder, Overactive | 2006 |
Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Cresols; Humans; Mandelic Acids; Muscarinic Antagonis | 2006 |
Male overactive bladder: the role of urodynamics and anticholinergics.
Topics: Adult; Aged; Benzhydryl Compounds; Cholinergic Antagonists; Cresols; Cystoscopy; Follow-Up Studies; | 2007 |
New developments in the treatment of urinary incontinence.
Topics: Administration, Cutaneous; Adrenergic Uptake Inhibitors; Benzofurans; Drug Therapy, Combination; Dul | 2006 |
Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials.
Topics: Benzhydryl Compounds; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Phenylpropanolamine; | 2007 |
Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential.
Topics: Benzhydryl Compounds; Benzilates; Cholinergic Antagonists; Cresols; Cytochrome P-450 Enzyme System; | 2007 |
Transdermal oxybutynin: a review.
Topics: Administration, Cutaneous; Humans; Mandelic Acids; Parasympatholytics; Treatment Outcome; Urinary Bl | 2007 |
Overactive bladder: recognition requires vigilance for symptoms.
Topics: Benzhydryl Compounds; Cost of Illness; Cresols; Female; Humans; Male; Mandelic Acids; Mass Screening | 2007 |
Update on drugs for overactive bladder syndrome.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Cholinergic Antagonists; Cresols; Humans; Mandelic Ac | 2007 |
Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.
Topics: Aged; Benzhydryl Compounds; Cresols; Delayed-Action Preparations; Female; Humans; Male; Mandelic Aci | 2007 |
Transdermal oxybutynin in the treatment of overactive bladder.
Topics: Administration, Topical; Benzhydryl Compounds; Cresols; Humans; Mandelic Acids; Parasympatholytics; | 2006 |
Pharmacologic management of overactive bladder.
Topics: Benzhydryl Compounds; Benzofurans; Cresols; Humans; Mandelic Acids; Muscarinic Antagonists; Nortropa | 2007 |
Evolution of transdermal oxybutynin in the treatment of overactive bladder.
Topics: Administration, Cutaneous; Clinical Trials as Topic; Evidence-Based Medicine; Humans; Mandelic Acids | 2008 |
Delivery methods for drugs used in the treatment of overactive bladder.
Topics: Animals; Drug Delivery Systems; Humans; Pharmaceutical Preparations; Transdermal Patch; Urinary Blad | 2016 |
54 trials available for oxybutynin and Bladder, Overactive
| Article | Year |
|---|---|
Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study.
Topics: Adolescent; Child; Humans; Mandelic Acids; Muscarinic Antagonists; Treatment Outcome; Urinary Bladde | 2023 |
Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study.
Topics: Adolescent; Child; Humans; Mandelic Acids; Muscarinic Antagonists; Treatment Outcome; Urinary Bladde | 2023 |
Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study.
Topics: Adolescent; Child; Humans; Mandelic Acids; Muscarinic Antagonists; Treatment Outcome; Urinary Bladde | 2023 |
Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study.
Topics: Adolescent; Child; Humans; Mandelic Acids; Muscarinic Antagonists; Treatment Outcome; Urinary Bladde | 2023 |
Effects of Treating an Overactive Urinary Bladder in Patients with Multiple Sclerosis.
Topics: Cholinergic Antagonists; Female; Humans; Male; Mandelic Acids; Middle Aged; Multiple Sclerosis; Qual | 2019 |
Effect of oxybutynin patch versus mirabegron on nocturia-related quality of life in female overactive bladder patients: A multicenter randomized trial.
Topics: Acetanilides; Double-Blind Method; Female; Humans; Mandelic Acids; Nocturia; Quality of Life; Thiazo | 2021 |
Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial.
Topics: Acetylcholine Release Inhibitors; Administration, Oral; Adult; Botulinum Toxins, Type A; Female; Fol | 2018 |
Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
Topics: Adult; Aged; Benzhydryl Compounds; Benzilates; Benzofurans; Blood Pressure; Female; Heart Rate; Huma | 2019 |
Prospective and randomized comparison of electrical stimulation of the posterior tibial nerve versus oxybutynin versus their combination for treatment of women with overactive bladder syndrome.
Topics: Adult; Aged; Combined Modality Therapy; Electric Stimulation Therapy; Female; Humans; Mandelic Acids | 2014 |
Multi-center randomized controlled trial of cognitive treatment, placebo, oxybutynin, bladder training, and pelvic floor training in children with functional urinary incontinence.
Topics: Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Humans; Male; Mandelic Acids | 2014 |
A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women.
Topics: Adult; Aged; Aged, 80 and over; Contraceptive Devices, Female; Double-Blind Method; Female; Humans; | 2014 |
Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial.
Topics: Adult; Aged; Aged, 80 and over; Benzilates; Double-Blind Method; Female; Humans; Male; Mandelic Acid | 2014 |
[Treatment of overactive bladder in older women increased doses of antimuscarinic drugs safe and effective alternative to existing methods].
Topics: Aged; Benzhydryl Compounds; Benzilates; Cresols; Dose-Response Relationship, Drug; Double-Blind Meth | 2014 |
Considering the prominent complaint as a guide in medical therapy for overactive bladder syndrome in women over 45 years.
Topics: Aged; Double-Blind Method; Female; Humans; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Tolt | 2015 |
Prominent complaint: a guide to medical therapy of overactive bladder syndrome in older women.
Topics: Aged; Benzhydryl Compounds; Cresols; Double-Blind Method; Female; Humans; Iran; Mandelic Acids; Midd | 2015 |
Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: A randomized, prospective, controlled multi-center trial.
Topics: Administration, Intravesical; Administration, Oral; Adult; Female; Humans; Male; Mandelic Acids; Pro | 2016 |
Once-daily oxybutynin patch improves nocturia and sleep quality in Japanese patients with overactive bladder: Post-hoc analysis of a phase III randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Double-Blind Method; Female; Humans; Japan; Male; Mand | 2015 |
Transcutaneous parasacral electrical stimulation vs oxybutynin for the treatment of overactive bladder in children: a randomized clinical trial.
Topics: Child; Comorbidity; Constipation; Female; Humans; Male; Mandelic Acids; Muscarinic Antagonists; Tran | 2015 |
Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Electric Stimulation Therapy; Female; Humans; Mandelic A | 2016 |
Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Electric Stimulation Therapy; Female; Humans; Mandelic A | 2016 |
Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Electric Stimulation Therapy; Female; Humans; Mandelic A | 2016 |
Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Electric Stimulation Therapy; Female; Humans; Mandelic A | 2016 |
Optimum Dose of Once-Daily Oxybutynin Patch in Japanese Patients with Overactive Bladder: A Randomized Double-Blind Trial Versus Placebo.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Administration Schedule; Female; Humans; M | 2016 |
Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder.
Topics: Aged; Aged, 80 and over; Chronic Disease; Drug Administration Schedule; Drug Therapy, Combination; F | 2017 |
The relevance of urodynamic studies for Urge syndrome and dysfunctional voiding: a multicenter controlled trial in children.
Topics: Adolescent; Age Factors; Chi-Square Distribution; Child; Electromyography; Female; Follow-Up Studies | 2008 |
Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study.
Topics: Aged; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Man | 2008 |
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Ge | 2009 |
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Ge | 2009 |
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Ge | 2009 |
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Ge | 2009 |
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Ge | 2009 |
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Ge | 2009 |
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Ge | 2009 |
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Ge | 2009 |
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Ge | 2009 |
Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study.
Topics: Adult; Aged; Cholinergic Antagonists; Female; Humans; Mandelic Acids; Middle Aged; Nocturia; Pilot P | 2009 |
The MATRIX study: assessment of health-related quality of life in adults with the use of transdermal oxybutynin.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Attitude to Health; Female; F | 2008 |
The MATRIX study: evaluating the data in older adults.
Topics: Activities of Daily Living; Adult; Age Factors; Aged; Aged, 80 and over; Attitude to Health; Female; | 2008 |
Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Topics: Adult; Chi-Square Distribution; Confidence Intervals; Czech Republic; Double-Blind Method; Female; H | 2010 |
Urgency-free time interval as primary endpoint for evaluating the outcome of a randomized OAB treatment.
Topics: Adult; Electric Stimulation Therapy; Endpoint Determination; Female; Health Surveys; Humans; Inciden | 2009 |
Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Child; Female; Humans; Male; Mandelic A | 2009 |
Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Child; Female; Humans; Male; Mandelic A | 2009 |
Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Child; Female; Humans; Male; Mandelic A | 2009 |
Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Child; Female; Humans; Male; Mandelic A | 2009 |
Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Child; Female; Humans; Male; Mandelic A | 2009 |
Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Child; Female; Humans; Male; Mandelic A | 2009 |
Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Child; Female; Humans; Male; Mandelic A | 2009 |
Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Child; Female; Humans; Male; Mandelic A | 2009 |
Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Child; Female; Humans; Male; Mandelic A | 2009 |
Double anticholinergic therapy for refractory overactive bladder.
Topics: Adolescent; Algorithms; Benzhydryl Compounds; Child; Cresols; Drug Therapy, Combination; Female; Hum | 2009 |
Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
Topics: Adult; Aged; Aged, 80 and over; Canada; Chi-Square Distribution; Double-Blind Method; Drug Administr | 2010 |
Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Epidemiologic Methods; Female; Goals; Hum | 2011 |
Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder.
Topics: Canada; Cost-Benefit Analysis; Female; Humans; Male; Mandelic Acids; Markov Chains; Muscarinic Antag | 2010 |
Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence.
Topics: Adolescent; Adult; Aged; Benzilates; Double-Blind Method; Female; Humans; Male; Mandelic Acids; Midd | 2010 |
Validity and reliability of the patient's perception of intensity of urgency scale in overactive bladder.
Topics: Adult; Epidemiologic Methods; Female; Humans; Mandelic Acids; Medical Records; Muscarinic Antagonist | 2011 |
[Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder].
Topics: Adolescent; Benzhydryl Compounds; Child; Child, Preschool; Cresols; Female; Humans; Male; Mandelic A | 2011 |
Validity and reliability of patient selected goals as an outcome measure in overactive bladder.
Topics: Female; Goals; Humans; Mandelic Acids; Muscarinic Antagonists; Patient Participation; Reproducibilit | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder.
Topics: Aged; Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Middle Aged; Muscari | 2011 |
Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference.
Topics: Administration, Cutaneous; Adult; Area Under Curve; Baths; Cholinergic Antagonists; Female; Gels; Hu | 2011 |
Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome.
Topics: Administration, Cutaneous; Aged; Double-Blind Method; Female; Gels; Humans; Mandelic Acids; Middle A | 2012 |
Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial.
Topics: Behavior Therapy; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Urinary Bladder | 2011 |
Patient-reported goal achievement after antimuscarinic treatment in patients with overactive bladder symptoms.
Topics: Aged; Female; Goals; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Patient Sati | 2012 |
An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Algorithms; Delayed-Action Preparations; Dose-Response | 2012 |
Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study.
Topics: Administration, Topical; Aged; Attention; Cognition; Double-Blind Method; Endpoint Determination; Fe | 2012 |
What is the success of drug treatment in urge urinary incontinence? What should be measured?
Topics: Adult; Benzhydryl Compounds; Benzilates; Cresols; Female; Humans; Mandelic Acids; Middle Aged; Musca | 2013 |
Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Analysis of Variance; Attention; Cognition; Cognitive D | 2013 |
Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Analysis of Variance; Attention; Cognition; Cognitive D | 2013 |
Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Analysis of Variance; Attention; Cognition; Cognitive D | 2013 |
Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Analysis of Variance; Attention; Cognition; Cognitive D | 2013 |
Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Analysis of Variance; Attention; Cognition; Cognitive D | 2013 |
Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Analysis of Variance; Attention; Cognition; Cognitive D | 2013 |
Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Analysis of Variance; Attention; Cognition; Cognitive D | 2013 |
Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Analysis of Variance; Attention; Cognition; Cognitive D | 2013 |
Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Analysis of Variance; Attention; Cognition; Cognitive D | 2013 |
Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects.
Topics: Aged; Analysis of Variance; Attention; Benzofurans; Delayed-Action Preparations; Double-Blind Method | 2006 |
Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.
Topics: Adolescent; Adult; Aged; Benzilates; Cholinergic Antagonists; Double-Blind Method; Female; Humans; M | 2007 |
Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
Topics: Adult; Aged; Benzhydryl Compounds; Cresols; Demography; Drug-Related Side Effects and Adverse Reacti | 2006 |
Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Electric Stimulation Therapy; Female; Humans; Mandelic A | 2006 |
Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.
Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Atropine; Cross-Over Studies; Doubl | 2007 |
Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Male; Mandeli | 2007 |
Rehabilitation versus drug therapy for urge urinary incontinence: long-term outcomes.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Mandelic Acids; Middle Aged; Muscarinic Antagonists; | 2008 |
Randomized trial of oxybutynin extended versus immediate release for women aged 65 and older with overactive bladder: lessons learned from conducting a trial.
Topics: Aged; Delayed-Action Preparations; Female; Humans; Mandelic Acids; Parasympatholytics; Prospective S | 2007 |
Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions.
Topics: Administration, Cutaneous; Adult; Aged; Health Status Indicators; Humans; Male; Mandelic Acids; Midd | 2008 |
Prospective randomized comparison of oxybutynin, functional electrostimulation, and pelvic floor training for treatment of detrusor overactivity in women.
Topics: Adult; Aged; Aged, 80 and over; Electric Stimulation Therapy; Female; Humans; Mandelic Acids; Middle | 2008 |
86 other studies available for oxybutynin and Bladder, Overactive
| Article | Year |
|---|---|
AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder.
Topics: Animals; Brain; Bridged Bicyclo Compounds, Heterocyclic; Carbachol; Cell Line, Transformed; CHO Cell | 2010 |
Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study.
Topics: Aged; Canada; Case-Control Studies; Dementia; Humans; Muscarinic Antagonists; Solifenacin Succinate; | 2022 |
The Twilight Zone: Oxybutynin Overuse Exacerbating Delirium.
Topics: Aged; Cholinergic Antagonists; Delirium; Humans; Male; Mandelic Acids; Urinary Bladder, Overactive | 2022 |
Oxybutynin nanosuspension gel for enhanced transdermal treatment for overactive bladder syndrome.
Topics: Administration, Cutaneous; Gels; Humans; Mandelic Acids; Muscarinic Antagonists; Urinary Bladder, Ov | 2022 |
The relationship between severity of overactive bladder symptoms and cognitive dysfunction, anxiety and depression in female patients with multiple sclerosis: Running head: OAB-V8, BICAMS and HAD scale in MS.
Topics: Adolescent; Anxiety; Child; Child, Preschool; Cognitive Dysfunction; Depression; Female; Humans; Mul | 2023 |
Effect of β3-adrenoceptor agonist on the micromotion of bilateral major pelvic ganglion-excised rat bladder.
Topics: Adrenergic beta-3 Receptor Agonists; Animals; Male; Rats; Rats, Sprague-Dawley; Receptors, Adrenergi | 2023 |
Open Label, Pilot Evaluation of the Safety and Efficacy of Intravesical Sustained Release System of Lidocaine and Oxybutynin (TRG-100) for Patients With Interstitial Cystitis/Bladder Pain Syndrome, Overactive Bladder and Patients With Retained Ureteral St
Topics: Administration, Intravesical; Cystitis, Interstitial; Delayed-Action Preparations; Humans; Lidocaine | 2023 |
[Assessment of prescribing practices in overactive bladder pharmacotherapy across different specialties of India: a prescription trend analysis].
Topics: Acetanilides; Humans; Muscarinic Antagonists; Prescriptions; Solifenacin Succinate; Tolterodine Tart | 2023 |
Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome.
Topics: Adult; Botulinum Toxins, Type A; Child; Cost-Benefit Analysis; Humans; Mandelic Acids; State Medicin | 2021 |
Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents.
Topics: Adolescent; Adult; Cholinergic Antagonists; Female; Humans; Male; Mandelic Acids; Medication Adheren | 2017 |
When Should We Offer Parasacral Transcutaneous Electrical Nerve Stimulation for Pediatric Patients with Lower Urinary Tract Dysfunction?
Topics: Child; Humans; Mandelic Acids; Transcutaneous Electric Nerve Stimulation; Urinary Bladder, Overactiv | 2017 |
[Tolerability, persistence and satisfaction. Retrospective cohort study in patients with overactive bladder syndrome treated with transdermal Oxybutynin under Standard ClinicAl pRactice. OSCAR Study.]
Topics: Administration, Cutaneous; Cohort Studies; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscar | 2017 |
[Maintenance of the efficacy of the oxybutynin patch for the treatment of overactive bladder syndrome despite the change in the area of application: study of four cases.]
Topics: Administration, Cutaneous; Aged; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antag | 2018 |
Cognitive function assessment in elderly patients with overactive bladder treated with transdermal oxybutynin.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Cognition; Female; Humans; Male; Mandelic Acids; | 2019 |
Overactive bladder - pharmacological treatment.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Antidepressive Agents; Benzilates; Benzofurans; B | 2019 |
A Nordic registry-based study of drug treatment patterns in overactive bladder patients.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Aged; Aged, 80 and over; Benzhydryl Compounds; Be | 2019 |
Reply from authors re: Jean-Nicolas Cornu. Overactive bladder medical management in the elderly: it is time to go beyond the tip of the iceberg. Eur Urol 2013;64:82-3.
Topics: Aging; Cognition; Cognitive Dysfunction; Female; Humans; Male; Mandelic Acids; Muscarinic Antagonist | 2013 |
[High patient satisfaction with the transdermal system].
Topics: Administration, Cutaneous; Clinical Trials as Topic; Female; Germany; Humans; Mandelic Acids; Medica | 2006 |
The use of oxybutynin in patients treated by means of botulinum neurotoxin A for neurogenic detrusor overactivity: an observational study.
Topics: Adult; Botulinum Toxins, Type A; Chi-Square Distribution; Dose-Response Relationship, Drug; Female; | 2013 |
Outcome of a standardized approach to childhood urinary symptoms-long-term follow-up of 720 patients.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Antidiuretic Agents; Biofeedback, Psychology; Child; Child | 2014 |
Gap junction expression and the effects of gap junction inhibitors in overactive bladder models: does ovariectomy have a role?
Topics: Analysis of Variance; Animals; Blotting, Western; Carbachol; Connexin 43; Disease Models, Animal; Fe | 2013 |
Does oxybutynin hydrochloride cause arrhythmia in children with bladder dysfunction?
Topics: Adolescent; Arrhythmias, Cardiac; Child; Child, Preschool; Electrocardiography; Female; Humans; Male | 2013 |
Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom.
Topics: Benzhydryl Compounds; Cohort Studies; Cost-Benefit Analysis; Cresols; Humans; Incontinence Pads; Man | 2013 |
Development of long-acting bioadhesive vaginal gels of oxybutynin: formulation, in vitro and in vivo evaluations.
Topics: Adhesiveness; Animals; Chitosan; Delayed-Action Preparations; Female; In Vitro Techniques; Mandelic | 2013 |
In brief: Oxytrol OTC.
Topics: Female; Humans; Mandelic Acids; Muscarinic Antagonists; Nonprescription Drugs; Transdermal Patch; Un | 2013 |
Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Benzilates; Cresols; Cross-Sectional Studies; Female; | 2014 |
Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
Topics: Administration, Intravesical; Adolescent; Adult; Age Factors; Child; Child, Preschool; Diagnostic Te | 2015 |
Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive, well tolerated alternative form of administration.
Topics: Administration, Cutaneous; Adolescent; Child; Child, Preschool; Female; Humans; Male; Mandelic Acids | 2014 |
In brief: Oxytrol OTC.
Topics: Administration, Cutaneous; Female; Humans; Mandelic Acids; Muscarinic Antagonists; Nonprescription D | 2013 |
Are oxybutynin and trospium efficacious in the treatment of detrusor overactivity in spinal cord injury patients?
Topics: Adult; Benzilates; Female; Humans; Male; Mandelic Acids; Nortropanes; Retrospective Studies; Spinal | 2014 |
A pilot prospective study to evaluate whether the bladder morphology in cystography and/or urodynamic may help predict the response to botulinum toxin a injection in neurogenic bladder refractory to anticholinergics.
Topics: Adult; Botulinum Toxins, Type A; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antag | 2014 |
Influence of antimuscarinic therapy on cognitive functions and quality of life in geriatric patients treated for overactive bladder.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Benzhydryl Compounds; Benzilates; Benzofurans; | 2015 |
Investigating detrusor muscle concentrations of oxybutynin after intravesical delivery in an ex vivo porcine model.
Topics: Administration, Intravesical; Animals; Mandelic Acids; Mucous Membrane; Muscarinic Antagonists; Musc | 2015 |
The Impact of Gene Polymorphisms on the Success of Anticholinergic Treatment in Children with Overactive Bladder.
Topics: Adolescent; Child; Child, Preschool; Cholinergic Antagonists; Cytochrome P-450 CYP3A; Female; Humans | 2015 |
Transdermal delivery of oxybutynin chloride proniosomal gels for the treatment of overactive bladder.
Topics: Administration, Cutaneous; Animals; Drug Stability; Gels; Hexoses; Lipids; Mandelic Acids; Skin; Uri | 2016 |
We should not use oxybutynin chloride in OAB.
Topics: Female; Humans; Male; Mandelic Acids; Muscarinic Antagonists; Urinary Bladder, Overactive; Urologica | 2017 |
Combined low-dose antimuscarinics for refractory detrusor overactivity in children.
Topics: Benzilates; Child; Drug Therapy, Combination; Female; Humans; Male; Mandelic Acids; Muscarinic Antag | 2016 |
Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Constipation; Female; Humans; Male; Mandelic Acids; Midd | 2018 |
[Expert opinion about the use of transdermic oxybutynin in Spain for the treatment of adult overactive bladder.]
Topics: Administration, Cutaneous; Adult; Expert Testimony; Humans; Mandelic Acids; Muscarinic Antagonists; | 2016 |
Pediatric voiding dysfunction: a case study.
Topics: Adolescent; Behavior Therapy; Causality; Cholinergic Antagonists; Combined Modality Therapy; Constip | 2008 |
The effects of reformulation: improved therapeutic index.
Topics: Benzhydryl Compounds; Benzilates; Chemistry, Pharmaceutical; Cresols; Humans; Mandelic Acids; Muscar | 2008 |
Protective action of intravesical oxybutynin on bladder ultrastructure in rabbits with detrusor overactivity.
Topics: Administration, Intravesical; Animals; Caveolae; Dose-Response Relationship, Drug; Intercellular Jun | 2009 |
Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.
Topics: Adolescent; Benzilates; Child; Child, Preschool; Epidemiologic Methods; Female; Humans; Infant; Male | 2009 |
Triple therapy in refractory detrusor overactivity: a preliminary study.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antidepressive Agents, Tricyclic; Child; Doxa | 2010 |
The MATRIX study: evaluating the data in older adults.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Attitude to Health; Dementia; Diapers, Ad | 2008 |
Editorial comment on: Cizolirtine citrate is safe and effective to treat urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Topics: Clinical Trials, Phase II as Topic; Humans; Mandelic Acids; Muscarinic Antagonists; Pyrazoles; Quali | 2010 |
Editorial comment on: Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Topics: Clinical Trials, Phase II as Topic; Humans; Mandelic Acids; Muscarinic Antagonists; Pyrazoles; Quali | 2010 |
Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study.
Topics: Administration, Cutaneous; Adolescent; Adult; Efficiency; Female; Humans; Male; Mandelic Acids; Midd | 2009 |
Urinary incontinence: oxybutynin topical gel for overactive bladder.
Topics: Administration, Topical; Female; Gels; Humans; Male; Mandelic Acids; Middle Aged; Randomized Control | 2009 |
Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Topics: Administration, Cutaneous; Adult; Drug Dosage Calculations; Female; Humans; Male; Mandelic Acids; Mi | 2009 |
Editorial comment.
Topics: Benzhydryl Compounds; Child; Cresols; Drug Therapy, Combination; Humans; Mandelic Acids; Muscarinic | 2009 |
Editorial comment.
Topics: Benzhydryl Compounds; Child; Cresols; Drug Therapy, Combination; Humans; Mandelic Acids; Muscarinic | 2009 |
Editorial comment.
Topics: Benzhydryl Compounds; Child; Cresols; Drug Therapy, Combination; Humans; Mandelic Acids; Muscarinic | 2009 |
The evolution of transdermal therapy for overactive bladder.
Topics: Administration, Cutaneous; Gels; Humans; Mandelic Acids; Muscarinic Antagonists; Urinary Bladder, Ov | 2009 |
The effect of intravesical oxybutynin on the ice water test and on electrical perception thresholds in patients with neurogenic detrusor overactivity.
Topics: Administration, Intravesical; Adolescent; Adult; Aged; Electrophysiological Phenomena; Female; Human | 2010 |
Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.
Topics: Adolescent; Benzilates; Child; Child, Preschool; Cholinergic Antagonists; Epidemiologic Methods; Fem | 2010 |
The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Topics: Benzhydryl Compounds; Benzilates; Cost-Benefit Analysis; Cresols; Decision Trees; Delayed-Action Pre | 2010 |
Pediatrics: combining antimuscarinics shows promise for overactive bladder.
Topics: Benzhydryl Compounds; Child; Cresols; Drug Therapy, Combination; Humans; Mandelic Acids; Muscarinic | 2010 |
Medication nonadherence secondary to drug-induced memory loss.
Topics: Aged; Female; Follow-Up Studies; Humans; Mandelic Acids; Medication Adherence; Memory Disorders; Mus | 2010 |
In women with urinary incontinence how necessary is cystometry?
Topics: Adult; Aged; Female; Humans; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Muscle Contraction | 2010 |
Oxybutynin and propiverine suppress adenosine triphosphate-induced bladder overactivity other than through antimuscarinic mechanisms.
Topics: Adenosine Triphosphate; Animals; Benzilates; Cholinergic Antagonists; Female; Mandelic Acids; Muscar | 2010 |
Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography.
Topics: Animals; Autoradiography; Benzofurans; Brain; Dose-Response Relationship, Drug; Imidazoles; Male; Ma | 2010 |
Intravesical oxybutynin protects the vesical wall against functional and smooth muscle changes in rabbits with detrusor overactivity.
Topics: Animals; Collagen; Elastic Tissue; Male; Mandelic Acids; Models, Animal; Muscle, Smooth; Parasympath | 2010 |
Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder.
Topics: Animals; Imidazoles; Male; Mandelic Acids; Muscarinic Antagonists; N-Methylscopolamine; Rats; Rats, | 2011 |
Idiopathic urgency urinary incontinence.
Topics: Cholinergic Antagonists; Female; Humans; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Prescr | 2010 |
A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Benzhydryl Compounds; Benzofurans; Blood-Bra | 2011 |
More treatment options for overactive bladder in postmenopausal women.
Topics: Contraceptive Devices, Female; Estradiol; Female; Humans; Mandelic Acids; Muscarinic Antagonists; Ur | 2011 |
Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: a multicentre, open-label, prospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug | 2012 |
Chronic use of oxybutynin and spinal anesthesia: a case of postoperative urinary retention and hematuria.
Topics: Ambulatory Surgical Procedures; Anesthesia, Spinal; Cholinergic Antagonists; Hematuria; Humans; Leg; | 2011 |
Bryophyllum pinnatum inhibits detrusor contractility in porcine bladder strips--a pharmacological study towards a new treatment option of overactive bladder.
Topics: Animals; Carbachol; Cholinergic Agonists; Electric Stimulation; Kalanchoe; Mandelic Acids; Muscarini | 2012 |
Combination of baclofen and antimuscarinics to reduce voiding difficulty in treating women with overactive bladders.
Topics: Adult; Aged; Baclofen; Benzhydryl Compounds; Community-Based Participatory Research; Cresols; Drug T | 2012 |
Overactive bladder medical management in the elderly: it is time to go beyond the tip of the iceberg.
Topics: Aging; Cognition; Cognitive Dysfunction; Female; Humans; Male; Mandelic Acids; Muscarinic Antagonist | 2013 |
Transdermal oxybutynin for overactive bladder.
Topics: Administration, Cutaneous; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; | 2006 |
Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin.
Topics: Benzhydryl Compounds; Comorbidity; Cresols; Delayed-Action Preparations; Depression; Female; Fractur | 2006 |
Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
Topics: Animals; Atropine; Benzhydryl Compounds; Benzilates; Benzofurans; Binding, Competitive; Carbachol; C | 2007 |
Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
Topics: Animals; Benzhydryl Compounds; Benzofurans; Cerebral Cortex; Cresols; In Vitro Techniques; Male; Man | 2007 |
Re: Rufus Cartwright and Linda Cardozo. Transdermal oxybutynin: sticking to the facts. Eur urol 2007;51:907-14.
Topics: Administration, Cutaneous; Female; Humans; Male; Mandelic Acids; Muscarinic Antagonists; Treatment O | 2007 |
Treatment of hyperhidrosis with oxybutynin.
Topics: Adult; Humans; Hyperhidrosis; Mandelic Acids; Muscarinic Antagonists; Parasympatholytics; Urinary Bl | 2007 |
Adsorptive stripping voltammetric behavior and determination of anticholinergic agent oxybutynin chloride on a mercury electrode.
Topics: Adsorption; Chemistry, Pharmaceutical; Cholinergic Antagonists; Electrochemistry; Electrodes; Humans | 2007 |
Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
Topics: Benzilates; Humans; Mandelic Acids; Parasympatholytics; Safety; Urinary Bladder, Overactive | 2007 |
Therapeutic effects of the putative P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats.
Topics: Animals; Cyclophosphamide; Cystitis; Disease Models, Animal; Dose-Response Relationship, Drug; Femal | 2008 |
In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder.
Topics: Administration, Oral; Animals; Area Under Curve; Benzhydryl Compounds; Benzilates; Cholinergic Antag | 2008 |
Better management of patients with overactive bladder with antimuscarinics?
Topics: Administration, Cutaneous; Evidence-Based Medicine; Humans; Male; Mandelic Acids; Muscarinic Antagon | 2008 |
Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
Topics: Adult; Aged; Benzhydryl Compounds; Cohort Studies; Cresols; Databases, Factual; Delayed-Action Prepa | 2008 |
Transdermal delivery of tolterodine tartrate for overactive bladder treatment: In vitro and in vivo evaluation.
Topics: Administration, Cutaneous; Animals; Male; Rats, Sprague-Dawley; Skin Absorption; Tolterodine Tartrat | 2017 |
Silicone adhesive, a better matrix for tolterodine patches-a research based on in vitro/in vivo studies.
Topics: Adhesives; Administration, Cutaneous; Animals; Benzhydryl Compounds; Biological Availability; Chemis | 2012 |